| NLEM | Molecule_Desc | Market | PACK_DESC | BRANDS | Unit | COMPANY | MAT May’12 Value | PTR May’12 | MAT % | PTR per unit | Ceiling Price with 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.3.2 | IUD-COPPER WIRE | IUD containing Copper | MULTILOAD CU 250 IUD x 1 | MULTILOAD | 1 | Organon (I | 44729595 | 320.00 | 60.42 | 320.00 | -- |
| 18.3.2 | IUD-COPPER WIRE | IUD containing Copper | MULTILOAD CU 375 IUD x 1 | MULTILOAD | 1 | Organon (I) | 25861337 | 481.60 | 34.93 | 481.60 | -- |
-- |
IUD-COPPER WIRE | IUD containing Copper | T care 200B | T care 200B | 1 | HLL Lifecar | 225985 | 96.00 | 0.31 | 96.00 | -- |
-- |
IUD-COPPER WIRE | IUD containing Copper | T Care 380A | T Care 380A | 1 | HLL Lifecar | 341147 | 100.00 | 0.46 | 100.00 | -- |
-- |
IUD-COPPER WIRE | IUD containing Copper | M care Cu 250 | M care Cu 25 | 1 | HLL Lifeca | 2058797 | 280.00 | 2.78 | 280.00 | -- |
-- |
IUD-COPPER WIRE | IUD containing Copper | N care Cu 375 | N care Cu 37 | 1 | HLL Lifecar | 810725 | 432.00 | 1.10 | 432.00 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
Total | 74027586 | -- |
100.00 | 284.93 | 330.52 |
-- |
maximum | 481.60 | minimum | 96.00 | |||||||
-- |
As per the above there are 2 companies consisting of Market Share of 1% & Above | -- |
-- |
-- |
|||||||
-- |
Sum of MAT value considered for price calculation | 740.28 | (Rs. in lakhs) | -- |
|||||||
-- |
Sum of PTR per unit considered for price calculation | 1709.60 | -- |
-- |
|||||||
-- |
Number of Packs considered | 6.00 | -- |
-- |
|||||||
-- |
Average PTR | 284.93 | -- |
-- |
|||||||
-- |
Add : 16% Retailer Margin | 45.59 | -- |
-- |
|||||||
-- |
Ceiling Price (without local taxes) | 330.52 | -- |
-- |
|||||||
-- |
% Reduction with compared to Highest Price | 40.84% | -- |
-- |
|||||||
-- |
WPI increase on 1 April, 2014 | 6.32% | -- |
||||||||
-- |
Ceiling Price after WPI Adjustment | 351.41 | S.O. 2349(E) dt. 15.9.2014 | -- |
|||||||
| NLEM | Molecule_Desc | Market | PACK_DESC | BRANDS | COMPANY | No. of Doses | MAT May’12 Value | PTR May’12 | MAT % | PTR per dose |
|---|---|---|---|---|---|---|---|---|---|---|
| 19.3.1.1 | VACCINE, BACILLUS CALMETTE-GUERIN | B.C.G Vaccine Injection | BCG VACCINE | BCG VACCINE | SERUM INS | 10 | 83339000 | 83.35 | 29763928.57 | 8.34 |
-- |
VACCINE, BACILLUS CALMETTE-GUERIN | B.C.G Vaccine Injection | BCG INJ DRY V | BCG | UNIDENT MA | 5 | 23661 | 23.22 | 8450.36 | 4.64 |
-- |
Total | 83362661 | -- |
29772378.93 | 8.34 | |||||
-- |
Monopoly situation as only M/s. Se | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
PTR per unit | -- |
-- |
8.34 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
Price fixed in the relevant sub-secti | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
19.3.1: For Universal Immunisation
| – | S.No. | Drugs | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price | Meeting No. | S.O.No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|---|
-- |
1 | B.C.G Vaccine | P,S,T | Injection | Not mentioned | Under consideration | -- |
-- |
-- |
-- |
-- |
2 | D.P.T Vaccine | P,S,T | Injection | Not mentioned | 232.86 | 1st | 1671 | 14.06.2013 | 47.67 |
-- |
3 | Hepatitis B Vaccine | P,S,T | Injection | Not mentioned | 101.09 | 8th | 3351 | 05.11.2013 | 78.15 |
-- |
4 | Measles Vaccine | P,S,T | Injection | Not mentioned | 252.97 | 8th | 3352 | 05.11.2013 | 44.53 |
-- |
5 | Oral Poliomyelitis vaccine (LA) | P,S,T | Solution | Not mentioned | 99.9 | 10th | 3374 (E) | 20.12.2013 | 12.21 |
-- |
Average | 45.64 | ||||||||
-- |
Therefore, PTR per unit | -- |
-- |
8.34 x(1-45.64%) | 4.53 | -- |
||||
-- |
Add: 16% Retailer Margin | -- |
-- |
-- |
0.72 | -- |
||||
-- |
Ceiling Price per unit | -- |
-- |
-- |
5.25 | -- |
||||
-- |
WPI @ 6.32% | -- |
-- |
-- |
0.33 | -- |
||||
-- |
Ceiling price with WPI | -- |
-- |
-- |
5.58 | per dose | S.O. 2356(E) dt. 15.9.2014 | -- |
||
| Molecule | Market | PACK_DESC | BRANDS | MANUFACTUR | COMPANY | MAT May’1 | PTR May’12 | -- |
||
-- |
||||||||||
| ENALAPRI | Enalapril Maleate Injection 1.25 mg/ml | ENVAS INJ AMP 1.25 MG 1 ML x 1 (/1ML) | ENVAS | CADILA PHARM | CADILA PHARMA | 11881948 | 167.86 | -- |
||
-- |
||||||||||
-- |
Monopoly situation as only M/s. Cadila Pharma | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
PTR per unit | -- |
-- |
167.86 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
Price fixed in the relevant sub-section for oth | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
12.3: Anti hypertensive medicines
| S.No. | Drugs | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price | Meeting No. | S.O.No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| 12.3.3 | Enalpril Maleate | P,S,T | Tablets | 2.5 mg | 1.78 | 1st | 1633 | 14.06.2013 | 6.75 |
| 12.3.3 | Enalpril Maleate | P,S,T | Tablets | 5 mg | 2.96 | 1st | 1634 | 14.06.2013 | 14.33 |
| 12.3.3 | Enalpril Maleate | T | Injection | 1.25mg/ml | Under consideration | -- |
-- |
||
-- |
Average | 10.54 | |||||||
-- |
Therefore, PTR per unit | -- |
-- |
167.86x(1-10.54%) | 150.17 | -- |
|||
-- |
Add: 16% Retailer Margin | -- |
-- |
-- |
24.03 | -- |
|||
-- |
Ceiling Price per unit | -- |
-- |
-- |
174.20 | -- |
|||
-- |
WPI @ 6.32% | -- |
-- |
-- |
11.01 | -- |
|||
-- |
Ceiling price with WPI | -- |
-- |
-- |
185.21 | S.O. 2357(E) dt. 15.9.2014 | -- |
||
| NLEM Un | Composition as per NLEM | PACK_DESC | BRANDS | MANUFACTU | Strength | Unit | Unit | MAT Sep’13 Value | MAT% | PTR Sep’13 | Price per Unit | Ceiling Price with 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.1.0.2 | Chlorpromazine hydrochloride Tablets 50 mg | CHLORPROMAZINE TABS 50 MG x 10 | CHLORPROMAZINE | SUN* | 50 | 10 | per tablet | 1712751 | 396470.14% | 3.36 | 0.34 | -- |
| 24.1.0.2 | Chlorpromazine hydrochloride Tablets 50 mg | CPZ FILM C.TABS 50 MG x 10 | CPZ | A.N.PHARMA | 50 | 10 | per tablet | 3617119 | 837296.06% | 3.36 | 0.34 | -- |
| 24.1.0.2 | Chlorpromazine hydrochloride Tablets 50 mg | EMETIL TABS 50 MG x 10 | EMETIL | LA PHARMA | 50 | 10 | per tablet | 1233262 | 285477.31% | 3.43 | 0.34 | -- |
-- |
-- |
6563132 | 1519243.52% | -- |
0.34 | 0.39 | ||||||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
maximum | 0.34 | minimum | 0.34 | -- |
-- |
As per the above there are 3 companies consisting of Market Share of 1% & Above | -- |
-- |
|||||||||
-- |
Sum of MAT value considered for price calculation | 65.63 | (Rs. In Lakhs) | -- |
||||||||
-- |
Sum of PTR per unit considered for price calculation | 1.02 | -- |
|||||||||
-- |
Number of Packs considered | 3 | -- |
|||||||||
-- |
Average PTR | 0.34 | -- |
|||||||||
-- |
Add : 16% Retailer Margin | 0.05 | -- |
|||||||||
-- |
Ceiling Price (without local taxes) | 0.39 | -- |
|||||||||
-- |
% Reduction with compared to Highest Price | 0.00% | -- |
|||||||||
-- |
-- |
-- |
-- |
|||||||||
-- |
WPI increase on 1 April, 2014 | 6.32% | -- |
|||||||||
-- |
Ceiling Price after WPI Adjustment | 0.41 | S.O. 2351(E) dt. 15.9.2014 | -- |
||||||||
| NLEM Unique No. | Composition as per NLEM | PACK_DESC | BRANDS | Company | Strength | Unit | Unit | MAT Sep’13 Value | MAT% | PTR Sep’13 | Price per Unit | Ceiling Price with 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.1.0. | Chlorpromazine hydrochloride Tablets 1 | CHLORPROMAZINE TABS 100 MG x 10 | CHLORPROMAZINE | SUN* | 100 | 10 | per tablet | 2839149 | 38.85 | 5.48 | 0.55 | -- |
| 24.1.0. | Chlorpromazine hydrochloride Tablets 1 | CPZ FILM C.TABS 100 MG x 10 | CPZ | A.N.PHARM | 100 | 10 | per tablet | 3122847 | 42.73 | 5.48 | 0.55 | -- |
| 24.1.0. | Chlorpromazine hydrochloride Tablets 1 | EMETIL TABS 100 MG x 10 | EMETIL | LA PHARM | 100 | 10 | per tablet | 1345939 | 18.42 | 5.45 | 0.55 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
7307935 | 100.00 | -- |
0.55 | 0.64 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
maximum | 0.55 | minimum | 0.55 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
As per the above there are 3 companies consi | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Sum of MAT value considered for price calculat | -- |
73.08 | (Rs. In Lak | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Sum of PTR per unit considered for price calcul | -- |
1.65 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Number of Packs considered | -- |
3 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average PTR | -- |
0.55 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Add : 16% Retailer Margin | -- |
0.09 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Ceiling Price (without local taxes) | -- |
0.64 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
% Reduction with compared to Highest Price | -- |
0.00% | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
WPI increase on 1 April, 2014 | -- |
6.32% | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Ceiling Price after WPI Adjustment | -- |
0.68 | S.O. 2351(E) | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
| S.No. | Formulation | PACK_DESC | Pack size | BRANDS | COMPANY | MAT Sep’13 Value | PTR Sep’13 | MAT % | PTR | Retailer Margin@16% |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | FLOXIP FILM C.TABS 250 MG x 10 | 10 | FLOXIP | ABBOTT* | 5566785 | 8.50 | 1.87 | 0.85 | -- |
| 2 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | CIPROWIN FILM C.TABS 250 MG x 10 | 10 | CIPROWIN | ALEMBIC | 18322245 | 10.50 | 6.14 | 1.05 | -- |
| 3 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | STROX FILM C.TABS 250 MG x 10 | 10 | STROX | ALEMBIC | 8623045 | 10.50 | 2.89 | 1.05 | -- |
| 4 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coated) | BAYCIP FILM C.TABS 250 MG x 10 | 10 | BAYCIP | BAYER ZYDUS PHARMA | 2756036 | 26.21 | 0.92 | 2.62 | -- |
| 5 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | CEBRAN FILM C.TABS 250 MG x 10 | 10 | CEBRAN | BLUE CROSS | 7532922 | 25.56 | 2.53 | 2.56 | -- |
| 6 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | CIPRODAC FILM C.TABS 250 MG x 10 | 10 | CIPRODAC | CADILA PHARMA | 3676060 | 9.25 | 1.23 | 0.93 | -- |
| 7 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | CIPLOX FILM C.TABS 250 MG x 10 | 10 | CIPLOX | CIPLA | 85237149 | 28.60 | 28.57 | 2.86 | -- |
| 8 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coated) | CIPROLET FILM C.TABS 250 MG x 10 | 10 | CIPROLET | DR REDDYS LABS | 1422802 | 26.53 | 0.48 | 2.65 | -- |
| 9 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | ZOXAN FILM C.TABS 250 MG x 10 | 10 | ZOXAN | FDC | 16871490 | 23.16 | 5.66 | 2.32 | -- |
| 10 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coated) | CIPRIND FILM C.TABS 250 MG x 10 | 10 | CIPRIND | INDOCO* | 421804 | 22.56 | 0.14 | 2.26 | -- |
| 11 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | CIFLOX FILM C.TABS 250 MG x 10 | 10 | CIFLOX | IND-SWIFT | 3084930 | 9.68 | 1.03 | 0.97 | -- |
| 12 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | SWIFLOX FILM C.TABS 250 MG x 10 | 10 | SWIFLOX | IND-SWIFT | 3714784 | 11.26 | 1.25 | 1.13 | -- |
| 13 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coated) | CIPROLAR FILM C.TABS 250 MG x 10 | 10 | CIPROLAR | LARK LABS | 271039 | 24.87 | 0.09 | 2.49 | -- |
| 14 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | CIPROVA FILM C.TABS 250 MG x 10 | 10 | CIPROVA | LUPIN LIMITED | 2907993 | 10.10 | 0.97 | 1.01 | -- |
| 15 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | LUCIPRO FILM C.TABS 250 MG x 10 | 10 | LUCIPRO | LUPIN LIMITED | 85934 | 8.10 | 0.03 | 0.81 | -- |
| 16 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coated) | MAFLO FILM C.TABS 250 MG x 10 | 10 | MAFLO | MAPRA LABS | 408035 | 21.53 | 0.14 | 2.15 | -- |
| 17 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | MICROFLOX FILM C.TABS 250 MG x 10 | 10 | MICROFLOX | MICRO LABS* | 12267906 | 25.51 | 4.11 | 2.55 | -- |
| 18 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | CIFRAN FILM C.TABS 250 MG x 10 | 10 | CIFRAN | RANBAXY* | 113687607 | 28.60 | 38.11 | 2.86 | -- |
| 19 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | CIPBID FILM C.TABS 250 MG x 10 | 10 | CIPBID | SHREYA LIFE SCIENC | 4764092 | 10.80 | 1.60 | 1.08 | -- |
| 20 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coat | QUINTOR FILM C.TABS 250 MG x 10 | 10 | QUINTOR | TORRENT PHARMA | 3964087 | 25.39 | 1.33 | 2.54 | -- |
| 21 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coated) | CIPBACT FILM C.TABS 250 MG x 10 | 10 | CIPBACT | UNICHEM* | 695527 | 8.22 | 0.23 | 0.82 | -- |
| 22 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coated) | CIPROTAB FILM C.TABS 250 MG x 10 | 10 | CIPROTAB | WOCKHARDT LTD* | 728981 | 13.50 | 0.24 | 1.35 | -- |
| 23 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coated) | BIOBID FILM C.TABS 250 MG x 10 | 10 | BIOBID | ZYDUS CADILA* | 84687 | 12.00 | 0.03 | 1.2 | -- |
| 24 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coated) | BIOCIP FILM C.TABS 250 MG x 10 | 10 | BIOCIP | ZYDUS CADILA* | 1132446 | 26.36 | 0.38 | 2.64 | -- |
| 25 | Ciprofloxacin Hydrochloride Tablets 250 mg (Coated) | GERCIP FILM C.TABS 250 MG x 10 | 10 | GERCIP | ZYDUS CADILA* | 89400 | 7.40 | 0.03 | 0.74 | -- |
-- |
-- |
298317786 | -- |
Average | 1.64 | 1.90 | ||||
-- |
-- |
-- |
-- |
-- |
-- |
Maximum | 2.86 | Minimum | 0.81 | -- |
-- |
As per above, there are 12 companies having Market share of 1% and above | -- |
-- |
-- |
||||||
-- |
Sum of MAT value considered for price calculation | 2,903.07 | (Rs. in Lakhs) | -- |
||||||
-- |
Sum of PTR per unit considered for price calculation | 24.57 | -- |
-- |
||||||
-- |
Number of Packs considered | 15 | -- |
-- |
||||||
-- |
Average PTR | 1.64 | -- |
-- |
||||||
-- |
Add : 16% Retailer Margin | 0.26 | -- |
-- |
||||||
-- |
Ceiling Price (without taxes) | 1.90 | -- |
-- |
||||||
-- |
% Reduction with compared to Highest Price | 42.66% | -- |
-- |
||||||
-- |
-- |
-- |
-- |
-- |
||||||
-- |
WPI increase on 1 April 2014 | 6.32% | -- |
|||||||
-- |
Ceiling Price after WPI Adjustment | 2.02 | S.O. 2352(E) dt. 15.9.2014 | -- |
||||||
| S.No. | NLEM | Molecule_Desc | Market | PACK_DESC | BRANDS | Pack size | COMPANY | MAT Sep’13 Value | PTR Sep’13 | MAT % | PTR per un | – |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | FLOXIP FILM | FLOXIP | 10 | ABBOTT* | 19250643 | 16.00 | 1.04% | 1.60 | -- |
| 2 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIFOMED TABS | CIFOMED | 10 | AGLOWMED | 18481947 | 49.44 | 0.99% | 4.94 | -- |
| 3 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROWIN FIL | CIPROWIN | 10 | ALEMBIC | 24916794 | 19.00 | 1.34% | 1.90 | -- |
| 4 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | STROX FILM C. | STROX | 10 | ALEMBIC | 13126369 | 17.00 | 0.71% | 1.70 | -- |
| 5 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | ALCIPRO FILM | ALCIPRO | 10 | ALKEM* | 127000827 | 52.95 | 6.84% | 5.30 | -- |
| 6 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | LOXY TABS 50 | LOXY | 10 | ALKEM* | 124609 | 19.68 | 0.01% | 1.97 | -- |
| 7 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | BAYCIP FILM | BAYCIP | 10 | BAYER ZYDUS PHA | 24655505 | 50.80 | 1.33% | 5.08 | -- |
| 8 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | QUFLOX FILM C | QUFLOX | 10 | BECKCEM | 45916 | 46.38 | 0.00% | 4.64 | -- |
| 9 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | XIPRO TABS 50 | XIPRO | 10 | BLISS | 631954 | 41.58 | 0.03% | 4.16 | -- |
| 10 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CEBRAN FILM | CEBRAN | 10 | BLUE CROSS | 31753006 | 44.66 | 1.71% | 4.47 | -- |
| 11 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPRODAC FIL | CIPRODAC | 10 | CADILA PHARMA | 27099845 | 17.50 | 1.46% | 1.75 | -- |
| 12 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPLOX FILM | CIPLOX | 10 | CIPLA | 417527787 | 55.00 | 22.47% | 5.50 | -- |
| 13 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPTEC TABS | CIPTEC | 10 | CIPLA | 303886 | 13.50 | 0.02% | 1.35 | -- |
| 14 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | NEOCIP TABS | NEOCIP | 10 | CIPLA | 416660 | 10.11 | 0.02% | 1.01 | -- |
| 15 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROLET FILM | CIPROLET | 10 | DR REDDYS LABS | 15500858 | 52.01 | 0.83% | 5.20 | -- |
| 16 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | ECIP FILM C.TA | ECIP | 10 | EAST WEST PHARMA | 358132 | 45.50 | 0.02% | 4.55 | -- |
| 17 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | ZUCIPRO TABS | ZUCIPRO | 10 | EMCURE* | 73779 | 21.50 | 0.00% | 2.15 | -- |
| 18 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | ZOXAN FILM C | ZOXAN | 10 | FDC | 91771420 | 45.48 | 4.94% | 4.55 | -- |
| 19 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPRIND FILM | CIPRIND | 10 | INDOCO* | 1347044 | 42.92 | 0.07% | 4.29 | -- |
| 20 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | SWIFLOX FILM | SWIFLOX | 10 | IND-SWIFT | 18328134 | 18.00 | 0.99% | 1.80 | -- |
| 21 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | C-FLOX TABS 5 | C-FLOX | 10 | INTAS PHARMA* | 3537905 | 16.00 | 0.19% | 1.60 | -- |
| 22 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROTAS TAB | CIPROTAS | 10 | INTAS PHARMA* | 1543499 | 17.00 | 0.08% | 1.70 | -- |
| 23 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | COUTIM FILM C | COUTIM | 10 | JAGSON PAL | 576504 | 18.50 | 0.03% | 1.85 | -- |
| 24 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CEFLOX TABS 5 | CEFLOX | 10 | LABORATE PHARMA | 6029304 | 16.00 | 0.32% | 1.60 | -- |
| 25 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROLAR FILM | CIPROLAR | 10 | LARK LABS | 134455 | 41.42 | 0.01% | 4.14 | -- |
| 26 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROLEB FILM | CIPROLEB | 10 | LEBEN LABS | 815039 | 32.26 | 0.04% | 3.23 | -- |
| 27 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CEEPRO TABS | CEEPRO | 10 | LINCOLN PHARMA | 2437029 | 51.32 | 0.13% | 5.13 | -- |
| 28 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROLUP TAB | CIPROLUP | 10 | LUPIN LIMITED | 798570 | 21.00 | 0.04% | 2.10 | -- |
| 29 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROVA FILM | CIPROVA | 10 | LUPIN LIMITED | 21370954 | 16.80 | 1.15% | 1.68 | -- |
| 30 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | LUCIPRO FILM | LUCIPRO | 10 | LUPIN LIMITED | 162432 | 17.27 | 0.01% | 1.73 | -- |
| 31 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROZOLE FI | CIPROZOLE | 10 | MANKIND | 26606539 | 46.00 | 1.43% | 4.60 | -- |
| 32 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | MAFLO FILM C.T | MAFLO | 10 | MAPRA LABS | 3890959 | 45.22 | 0.21% | 4.52 | -- |
| 33 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPTAB TABS | CIPTAB | 10 | MICRO LABS* | 385390 | 18.00 | 0.02% | 1.80 | -- |
| 34 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | MICROFLOX FI | MICROFLOX | 10 | MICRO LABS* | 76910063 | 49.44 | 4.14% | 4.94 | -- |
| 35 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | ICIP TABS 500 | ICIP | 10 | NOEL PHARMA | 951532 | 20.80 | 0.05% | 2.08 | -- |
| 36 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROCURE FIL | CIPROCURE | 10 | RADICURA PHARMA | 243293 | 38.50 | 0.01% | 3.85 | -- |
| 37 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIFRAN FILM | CIFRAN | 10 | RANBAXY* | 607671276 | 55.00 | 32.70% | 5.50 | -- |
| 38 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPRACT TABS | CIPRACT | 10 | RANBAXY* | 9538079 | 14.64 | 0.51% | 1.46 | -- |
| 39 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | QUINTOR FIL | QUINTOR | 10 | TORRENT PHARMA | 28703717 | 49.21 | 1.54% | 4.92 | -- |
| 40 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPBACT FILM | CIPBACT | 10 | UNICHEM* | 367514 | 16.20 | 0.02% | 1.62 | -- |
| 41 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROTAB FILM | CIPROTAB | 10 | WOCKHARDT LTD* | 7819661 | 17.95 | 0.42% | 1.80 | -- |
| 42 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROSYN TAB | CIPROSYN | 10 | WOCKHARDT LTD* | 70171 | 16.00 | 0.00% | 1.60 | -- |
| 43 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROZEN-F TA | CIPROZEN-F | 10 | ZENITH LABS | 329098 | 45.63 | 0.02% | 4.56 | -- |
| 44 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | BIOBID FILM | BIOBID | 10 | ZYDUS CADILA* | 395991 | 15.21 | 0.02% | 1.52 | -- |
| 45 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | BIOCIP FILM C | BIOCIP | 10 | ZYDUS CADILA* | 10299714 | 52.80 | 0.55% | 5.28 | -- |
| 46 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | CIPROBID FIL | CIPROBID | 10 | ZYDUS CADILA* | 213605318 | 52.53 | 11.50% | 5.25 | -- |
| 47 | 6.2.2.3 | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Hydrochloride Tablets 500 mg | GERCIP FILM | GERCIP | 10 | ZYDUS CADILA* | 176029 | 12.00 | 0.01% | 1.20 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
1858085150 | -- |
100.00% | 3.13 | 3.63 |
-- |
Maximum | 5.50 | Minimum | 1.01 | -- |
|||||||
-- |
As per above, there are 14 companies having Market share of 1% and above | -- |
-- |
|||||||||
-- |
Sum of MAT value considered for price calculation | 17,745.71 | (Rs. in la | -- |
||||||||
-- |
Sum of PTR per unit considered for price calculation | 78.16 | -- |
-- |
||||||||
-- |
Number of Packs considered | 25 | -- |
-- |
||||||||
-- |
Average PTR | 3.13 | -- |
-- |
||||||||
-- |
Add : 16% Retailer Margin | 0.50 | -- |
-- |
||||||||
-- |
Ceiling Price (without taxes) | 3.63 | -- |
-- |
||||||||
-- |
% Reduction with compared to Highest Price | 43.09% | -- |
-- |
||||||||
-- |
-- |
-- |
-- |
-- |
||||||||
-- |
WPI increase on 1 April 2014 | 6.32% | -- |
|||||||||
-- |
Ceiling Price after WPI Adjustment | 3.86 | S.O. 2352(E) dt. 15.9.2014 | -- |
||||||||
RIFAMPICIN 300MG TABLET
| NLEM | SKU | COMPANY | Value Sum of MAT UNIT SEPT 13 | Pack size | Sum of MAT VALUE SEPT 13 | MAT % | PTR | PTR per tab | PTR with Retailer Margin@16% | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.2.3.3.2 | MACOX 300 MG TABLET 6 | MACLEODS PHARMACEUTICALS PVT.LTD | 89475.0 | 6 | 1386445.8 | 90.19% | 13.74 | 2.29 | -- |
|||
-- |
MONOCIN 300 MG TABLET 10 | OVERSEAS HEALTHCARE PVT LTD. | 6304.0 | 10 | 137510.1 | 8.95% | 21.81 | 2.18 | -- |
|||
-- |
RF 300 MG TABLET 10 | SUNIJ PHARMA PVT LTD | 539.0 | 10 | 13286.4 | 0.86% | 22.90 | 2.29 | -- |
|||
-- |
Grand Total | -- |
96318.0 | -- |
1537242.3 | 100.00% | Average | 2.24 | 2.60 | -- |
||
-- |
Maximum | 2.29 | Minimum | 2.18 | -- |
|||||||
-- |
As per above, there are 2 companies having Market share of 1% and above | -- |
-- |
-- |
||||||||
-- |
Sum of MAT value considered for price calculation | 15.24 | (Rs. in la | -- |
||||||||
-- |
Sum of PTR per unit considered for price calculation | 4.47 | -- |
-- |
||||||||
-- |
Number of Packs considered | 2 | -- |
-- |
||||||||
-- |
Average PTR | 2.24 | -- |
-- |
-- |
-- |
||||||
-- |
Add : 16% Retailer Margin | 0.36 | -- |
-- |
-- |
-- |
||||||
-- |
Ceiling Price (without taxes) | 2.60 | -- |
-- |
-- |
-- |
||||||
-- |
% Reduction with compared to Highest Price | 2.18% | -- |
-- |
-- |
-- |
-- |
|||||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||||
-- |
WPI increase on 1 April 2014 | 6.32% | -- |
-- |
-- |
-- |
||||||
-- |
Ceiling Price after WPI Adjustment | 2.76 | S.O. 2354(E) dt. 15.9.2014 | -- |
||||||||
RIFAMPICIN 450MG TABLET
| NLEM | SKU | COMPANY | Values Sum of MAT UNIT SEPT 13 |
Pack size | Sum of MAT VALUE SEPT 13 | MAT % | PTR | PTR per tab | PTR with Retailer Margin@16% | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.2.4.5 | MONOCIN 450 MG TABLET 10 | OVERSEAS HEALTHCARE PVT LTD. | 18721.0 | 10 | 591209.18 | 93.03% | 31.58 | 3.16 | -- |
|||
-- |
RF 450 MG TABLET 10 | SUNIJ PHARMA PVT LTD | 229.0 | 10 | 7685.63 | 1.21% | 33.50 | 3.35 | -- |
|||
-- |
RIMACTANE 450 MG TABLET 4 | NOVARTIS INDIA LTD | 2214.0 | 4 | 36596.88 | 5.76% | 13.40 | 3.35 | -- |
|||
-- |
Grand Total | -- |
21164.0 | -- |
635491.69 | 100.00% | Average | 3.29 | 3.82 | -- |
||
-- |
Maximum | 3.35 | Minimum | 3.16 | -- |
|||||||
-- |
As per above, there are 3 companies having Market share of 1% and above | -- |
-- |
-- |
||||||||
-- |
Sum of MAT value considered for price calculation | 6.35 | (Rs. in la | -- |
||||||||
-- |
Sum of PTR per unit considered for price calculation | 9.86 | -- |
-- |
||||||||
-- |
Number of Packs considered | 3 | -- |
-- |
||||||||
-- |
Average PTR | 3.29 | -- |
-- |
-- |
-- |
||||||
-- |
Add : 16% Retailer Margin | 0.53 | -- |
-- |
-- |
-- |
||||||
-- |
Ceiling Price (without taxes) | 3.82 | -- |
-- |
-- |
-- |
||||||
-- |
% Reduction with compared to Highest Price | 1.79% | -- |
-- |
-- |
-- |
-- |
|||||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||||
-- |
WPI increase on 1 April 2014 | 6.32% | -- |
-- |
-- |
-- |
||||||
-- |
Ceiling Price after WPI Adjustment | 4.06 | S.O. 2354(E) dt. 15.9.2014 | -- |
||||||||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Company | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
16.0.1.2 | Furosemide Tablets 40mg | LASIX TAB UNCOATED 40 MG x 15 | LASIX | SANOFI* | 40 | 15 | TABS | 97765568 | 99.95% | 5.46 | 0.36 |
-- |
-- |
Furosemide Tablets 40mg | Frusenex 40mg Tablet | Frusenex 40mg | Geno Pharmaceuticals | 40 | 10 | TABS | 44062 | 0.05% | 3.5 | 0.35 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
97809630 | 100.00% | -- |
-- |
-- |
-- |
Monopoly situation as M/s Sanofi is the only company manufacturing the formulation and has market share of 100% | -- |
-- |
||||||||
-- |
-- |
PTR per unit | -- |
0.36 | -- |
-- |
||||||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
||||||||
-- |
-- |
Section: 16 –Diuretics | -- |
-- |
-- |
-- |
-- |
|||||
-- |
-- |
Medicines | Category | Route of Admn | Strengths | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | -- |
-- |
-- |
-- |
Furosemide | P,S,T | Injection | 10 mg/ ml | To be consi | -- |
-- |
-- |
25.93% | -- |
-- |
-- |
-- |
Furosemide | P,S,T | Tablets | 40mg | Under con | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Hydrochlorothiazide | P,S,T | Tablets | 25 mg | 1.66 | 1st | 1640 | 14.6.2013 | 20.78% | -- |
-- |
-- |
-- |
Hydrochlorothiazide | P,S,T | Tablets | 50 mg | Data Not Available | -- |
-- |
-- |
-- |
-- |
|
-- |
-- |
Mannitol | P,S,T | Injection | 10% | 0.23 | 9th | 3572(E) | 02.12.2013 | 2.50% | -- |
-- |
-- |
-- |
Mannitol | P,S,T | Injection | 20% | 0.35 | 4th | 2062 | 05.07.2013 | 54.50% | -- |
-- |
-- |
-- |
Spironolactone | P,S,T | Tablets | 25 mg | To be consi | -- |
-- |
-- |
25.93% | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average % Reduction | 25.93% | -- |
-- |
-- |
-- |
Therefore, PTR per unit | 0.36 X (1-25.93%) | 0.27 | -- |
-- |
||||||
-- |
-- |
Add: 16% Retailer Margin | -- |
0.04 | -- |
-- |
||||||
-- |
-- |
Ceiling Price per unit | -- |
0.31 | -- |
-- |
||||||
-- |
-- |
-- |
-- |
-- |
-- |
|||||||
-- |
WPI increase on 1 April, 2014 | 0.02 | -- |
|||||||||
-- |
Ceiling Price after WPI Adjustment | 0.33 | S.O. 2360(E) dt. 15.9.2014 | -- |
||||||||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Company | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
16.0.1.1 | Furosemide Injection 10 mg/ ml | LASIX INJ AMP 10 MG 2 ML x 1 (/1ML) | LASIX | SANOFI* | 10mg | 2 | ML | 77654065 | 100.00% | 2.46 | 1.23 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
77654065 | -- |
-- |
-- |
-- |
-- |
Monopoly situation as M/s Sanofi is the only company manufacturing the formulation and has market share of 100% | -- |
|||||||||
-- |
-- |
PTR per unit | -- |
1.23 | -- |
|||||||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
|||||||||
-- |
-- |
Section: 16 –Diuretics | -- |
-- |
-- |
-- |
||||||
-- |
-- |
Medicines | Category | Route of Admn | Strengths | Ceiling price excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | -- |
|
-- |
-- |
Furosemide | P,S,T | Injection | 10 mg/ ml | Under con | -- |
-- |
-- |
-- |
-- |
|
-- |
-- |
Furosemide | P,S,T | Tablets | 40mg | To be consi | -- |
-- |
-- |
25.93% | -- |
|
-- |
-- |
Hydrochlorothiazide | P,S,T | Tablets | 25 mg | 1.66 | 1st | 1640 | 14.6.2013 | 20.78% | -- |
|
-- |
-- |
Hydrochlorothiazide | P,S,T | Tablets | 50 mg | Data Not Available | -- |
-- |
||||
-- |
-- |
Mannitol | P,S,T | Injection | 10% | 0.23 | 9th | 3572(E) | 02.12.2013 | 2.50% | -- |
|
-- |
-- |
Mannitol | P,S,T | Injection | 20% | 0.35 | 4th | 2062 | 05.07.2013 | 54.50% | -- |
|
-- |
-- |
Spironolactone | P,S,T | Tablets | 25 mg | To be consi | -- |
-- |
-- |
25.93% | -- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average % Reduction | 25.93% | -- |
|
-- |
-- |
Therefore, PTR per unit | 1.23 X (1-25.93%) | 0.91 | -- |
-- |
||||||
-- |
-- |
Add: 16% Retailer Margin | -- |
0.15 | -- |
-- |
||||||
-- |
-- |
Ceiling Price per unit | -- |
1.06 | -- |
-- |
||||||
-- |
-- |
-- |
-- |
-- |
||||||||
-- |
WPI increase on 1 April, 2014 | 0.07 | -- |
|||||||||
-- |
Ceiling Price after WPI Adjustment | 1.13 | S.O. 2360(E) dt. 15.9.2014 | -- |
||||||||
RIFAMPICIN 150MG TABLET
| Source | SKU | COMPANY | Sum of MAT UNIT SEPT 13 | Sum of MAT VALUE SEPT 13 | Pack size | PTR | PTR per tablet |
|---|---|---|---|---|---|---|---|
| Pharma | R-CIN 150 MG TABLET 20 | LUPIN LTD | 2486.0 | 71099.6 | 20 | 24.4 | 1.22 |
-- |
|||||||
-- |
Monopoly situation as only M/s. Lupin is the known manufacturer | -- |
-- |
-- |
-- |
||
-- |
PTR per unit | -- |
-- |
-- |
1.22 | -- |
-- |
-- |
Price fixed in the relevant sub-section for other similar drugs is as follows: | -- |
-- |
-- |
-- |
||
| 6.2.3:Antileprosy medicines | -- |
||||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price | Meeting No. | S.O.No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Clofazimine | P,S,T | Capsules | 50 mg | 1.28 | 1st | 1581 | 14.06.2013 | 15.00 |
| 2 | Clofazimine | Capsules | 100 mg | 2.22 | 1st | 1582 | 14.06.2013 | 22.19 | |
| 3 | Dapsone | Tablets | 50 mg | 0.20 | 7th | 2835 (E) | 20.09.2013 | 18.60 | |
| 4 | Dapsone | Tablets | 100 mg | 0.22 | 7th | 2836 (E) | 20.09.2013 | 18.60 | |
-- |
Average reduction | 18.60 | |||||||
-- |
Therefore, PTR per unit | -- |
-- |
1.22 x(1-18.60%) | 0.99 | -- |
|||
-- |
Add: 16% Retailer Margin | -- |
-- |
-- |
0.16 | -- |
|||
-- |
Ceiling Price per unit | -- |
-- |
-- |
1.15 | -- |
|||
-- |
WPI @ 6.32% | -- |
-- |
-- |
0.07 | -- |
|||
-- |
Ceiling price with WPI | -- |
-- |
-- |
1.22 | S.O. 2360(E) dt. 15.9.2014 | -- |
||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Company | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
16.0.1.4 | Spironolactone Tablets 25 mg | ALDACTONE TAB UNCOATED 25 MG x 15 | ALDACTONE | RPG LIFE SCIENCES | 25 | 15 | TABS | 50111219 | 100.00% | 19.93 | 1.33 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
50111219 | -- |
-- |
-- |
-- |
-- |
Monopoly situation as M/s RPG Life Science is the only company manufacturing the formulation and has market share of 100% | -- |
|||||||||
-- |
-- |
PTR per unit | -- |
1.33 | -- |
|||||||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
|||||||||
-- |
-- |
Section: 16 –Diuretics | -- |
-- |
-- |
-- |
||||||
-- |
-- |
Medicines | Category | Route of Admn | Strengths | Ceiling price excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | -- |
|
-- |
-- |
Furosemide | P,S,T | Injection | 10 mg/ ml | To be consi | -- |
-- |
-- |
25.93% | -- |
|
-- |
-- |
Furosemide | P,S,T | Tablets | 40mg | To be consi | -- |
-- |
-- |
25.93% | -- |
|
-- |
-- |
Hydrochlorothiazide | P,S,T | Tablets | 25 mg | 1.66 | 1st | 1640 | 14.6.2013 | 20.78% | -- |
|
-- |
-- |
Hydrochlorothiazide | P,S,T | Tablets | 50 mg | Data Not A | -- |
-- |
-- |
-- |
-- |
|
-- |
-- |
Mannitol | P,S,T | Injection | 10% | 0.23 | 9th | 3572(E) | 02.12.2013 | 2.50% | -- |
|
-- |
-- |
Mannitol | P,S,T | Injection | 20% | 0.35 | 4th | 2062 | 05.07.2013 | 54.50% | -- |
|
-- |
-- |
Spironolactone | P,S,T | Tablets | 25 mg | Under con | -- |
-- |
-- |
-- |
-- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average % Reduction | 25.93% | -- |
|
-- |
-- |
Therefore, PTR per unit | 1.33 X (1-25.93%) | 0.99 | -- |
|||||||
-- |
-- |
Add: 16% Retailer Margin | -- |
0.16 | -- |
|||||||
-- |
-- |
Ceiling Price per unit | -- |
1.15 | -- |
|||||||
-- |
-- |
-- |
-- |
-- |
||||||||
-- |
WPI increase on 1 April, 2014 | 0.07 | -- |
|||||||||
-- |
Ceiling Price after WPI Adjustment | 1.22 | S.O. 2360(E) dt. 15.9.2014 | -- |
||||||||
SULPHADIAZINE 500 MG TABLET
| Source | SKU | COMPANY | Values Sum of MAT UNIT SEP 13 |
Sum of MAT VAUE SEPT 13 | PTR | PTR per tablet |
|---|---|---|---|---|---|---|
| Pharma data | SULPHADIAZINE 500 MG TABLET 10 | ABOTT HEALTHCARE PVT. LTD. | 214.0 | 2534.0 | 9.20 | 0.92 |
-- |
Grand Total | -- |
214.0 | 2534.0 | -- |
-- |
-- |
Monopoly situation as only M/s. Abott is the k | -- |
-- |
-- |
-- |
-- |
-- |
PTR per unit | -- |
-- |
0.92 | -- |
-- |
-- |
Price fixed in the relevant sub-section for oth | -- |
-- |
-- |
-- |
-- |
6.2.2 Othe antibacterials
| S.No. | Drugs | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price | Meeting No. | S.O.No. | Date | % Reduction w.r.t. Highest Price |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Amikacin | S,T | Injection | 250 mg/2 ml | 13.96 | 2nd | 1801 | 21.6.2013 | 56.43% |
| 2 | Azithromycin | S,T | Tablets | 100 mg | 5.13 | 4th | 2051 | 05.07.2013 | 36.19% |
| 3 | Azithromycin | S,T | Tablets | 250 mg | 10.26 | 4th | 2052 | 05.07.2013 | 54.23% |
| 4 | Azithromycin | S,T | Tablets | 500 mg | 20.51 | 8th | 3379 | 05.11.2013 | 55.10% |
| 5 | Azithromycin | S,T | Suspension | 100mg/5ml | 1.55 | 5th | 2237 | 22.07.2013 | 50.83% |
| 6 | Azithromycin | S,T | Injection | 500 mg | 182.27 | 1st | 1578 | 14.06.2013 | 11.30% |
| 7 | Ciprofloxacin Hydrochloride | P,S,T | Injection | 200 mg/100 ml | 0.16 | 14th | 1157 (E) | 28.04.2014 | 6.67% |
| 8 | Ciprofloxacin Hydrochloride | P,S,T | Tablets | 250 mg | 1.90 | To be considered in 18 th meeting | 42.66% | ||
| 9 | Ciprofloxacin Hydrochloride | P,S,T | Tablets | 500 mg | 3.63 | To be considered in 18 th meeting | 43.09% | ||
| 10 | Co-Trimoxazole (Trimethoprim + Sulphamethoxazole) | P,S,T | Tablets | 80+400 mg | 0.55 | To be considered in 18 th meeting | 5.27% | ||
| 11 | Co-Trimoxazole (Trimethoprim + Sulphamethoxazole) | P,S,T | Tablets | 160+800 mg | 1.28 | 14th | 1157 (E) | 28.04.2014 | 5.98% |
| 12 | Co-Trimoxazole (Trimethoprim + Sulphamethoxazole) | P,S,T | Suspension | 40+200 mg/5 ml | 0.24 | 14th | 1157 (E) | 28.04.2014 | 4.55% |
| 13 | Doxycycline | P,S,T | Tablets | 100 mg | 0.94 | 14th | 1157 (E) | 28.04.2014 | 1.22% |
| 14 | Erythromycin Estolate | P,S,T | Syrup | 125 mg/5 ml | Data not available | -- |
|||
| 15 | Erythromycin Estolate | P,S,T | Tablets | 250 mg | Data not available | -- |
|||
| 16 | Erythromycin Estolate | P,S,T | Tablets | 500 mg | Data not available | -- |
|||
| 17 | Gentamicin | P,S,T | Injection | 10 mg/ml | Data not available | -- |
|||
| 18 | Gentamicin | P,S,T | Injection | 40 mg/ml | 2.18 | 14th | 1157 (E) | 28.04.2014 | 42.68% |
| 19 | Metronidazole | P,S,T | Tablets | 200 mg/100 ml | Data not available | -- |
|||
| 20 | Metronidazole | P,S,T | Tablets | 400 mg | Data not available | -- |
|||
| 21 | Metronidazole | P,S,T | Injection | 500 mg/100 ml | Data not available | -- |
|||
| 22 | Metronidazole | P,S,T | Syrup | 100 mg/5ml | 0.16 | 13th | 1012(E) | 02.04.2014 | 0.00 |
| 23 | Nitrofurantoin | P,S,T | Tablets | 100 mg | 6.88 | 3rd | 1885 | 28.06.2013 | 27.57% |
| 24 | Sulphadiazine | S,T | Tablets | 500 mg | Under consideration | -- |
|||
| 25 | Vancomycin Hydrochloride | P,S,T | Injection | 500 mg | 330.60 | 1st | 1579 | 14.6.2013 | 27.37% |
| 26 | Vancomycin Hydrochloride | P,S,T | Injection | 1 g | 514.44 | 1st | 1580 | 14.6.2013 | 15.10% |
-- |
-- |
-- |
Average | 27.01% | |||||
-- |
Therefore, PTR per unit | -- |
-- |
0.92 x(1-27.01%) | 0.67 | -- |
|||
-- |
Add: 16% Retailer Margin | -- |
-- |
-- |
0.11 | -- |
|||
-- |
Ceiling Price per unit | -- |
-- |
-- |
0.78 | -- |
|||
-- |
WPI @ 6.32% | -- |
-- |
-- |
0.05 | -- |
|||
-- |
Ceiling price with WPI | -- |
-- |
-- |
0.83 | S.O. 2360(E) dt. 15.9.2014 | -- |
||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Company | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
27.0.8.3 | Vitamin A Injection 50000 IU/ml | AQUASOL-A INJ IM. AMP 50 K 2 ML x 1 (/1ML) | AQUASOL-A | U S V | 50000 | 2 | ML | 1140794 | 100.00% | 2.84 | 1.42 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
1140794 | -- |
-- |
-- |
-- |
-- |
Monopoly situation as M/s USV is the only company manufacturing the formulation and has market share of 100% | -- |
|||||||||
-- |
-- |
PTR per unit | -- |
1.42 | -- |
|||||||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
|||||||||
| Section: 27 – Vitamins and Minerals | -- |
-- |
-- |
|||||||||
| – | – | Medicines | Category | Route of Administration/ Dosage Form | Strengths | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | – | |
-- |
1 | Ascorbic Acid | P,S,T | Tablets | 100 mg | Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
2 | Ascorbic Acid | P,S,T | Tablets | 500 mg | Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
3 | Calcium carbonate | P,S,T | Tablets | 250 mg | 1.68 | 7th | 2867(E) | 20.09.2013 | 18.45% | -- |
|
-- |
4 | Calcium carbonate | P,S,T | Tablets | 500 mg | 1.67 | 5th | 2255 (E) | 22.07.2013 | 24.33% | -- |
|
-- |
5 | Multivitamins (As per Schedule V of Drugs and Cosmetics Rules) | P,S,T | Tablets | -- |
Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
6 | Nicotinamide | P,S,T | Tablets | 50 mg | Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
7 | Pyridoxine | P,S,T | Tablets | 25 mg | Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
8 | Riboflavin | P,S,T | Tablets | 5 mg | Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
9 | Thiamine | P,S,T | Tablets | 100 mg | Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
10 | Vitamin A | P,S,T | Tablets | 5000 IU | Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
11 | Vitamin A | P,S,T | Capsules | 50000 IU | Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
12 | Vitamin A | P,S,T | Capsules | 100000 IU | Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
13 | Vitamin A | P,S,T | Injection | 50000 IU/ml | Under consi | -- |
-- |
-- |
-- |
-- |
|
-- |
14 | Vitamin D (Ergocalciferol) | P,S,T | Capsules | 0.25 mg | Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
15 | Vitamin D (Ergocalciferol) | P,S,T | Capsules | 1 mg | Data not ava | -- |
-- |
-- |
-- |
-- |
|
-- |
-- |
Added Medicines | -- |
-- |
-- |
-- |
-- |
-- |
||||
-- |
16 | Calcium Gluconae | P,S,T | Injection | 100mg/ml in 10 ml Ampoule | 9.95 | 7th | 2868 (E) | 20.09.2013 | 35.67% | -- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction | 26.15% | -- |
||
-- |
Therefore, PTR per unit | 1.42 X (1-26.15%) | 1.05 | -- |
||||||||
-- |
Add: 16% Retailer Margin | -- |
0.17 | -- |
||||||||
-- |
Ceiling Price per unit | -- |
1.22 | -- |
||||||||
-- |
-- |
-- |
-- |
-- |
||||||||
-- |
WPI increase on 1 April, 2014 | 0.08 | -- |
|||||||||
-- |
Ceiling Price after WPI Adjustment | 1.30 | S.O. 2360(E) dt. 15.9.2014 | -- |
||||||||
| Source of Data-IMS and Pharma trac ( Sep, 2013) | -- |
-- |
||||||||||
| S.No. | Composition of the formulation | Company | Dosage Form | Pack Size (In Ml) | MAT Units | Price to Retailer (Rs.) | MAT Value | MAT % | Price per ml | Ceiling Price with 16 % Margin | – | |
-- |
Prednisolone | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|
| 1 | ALCON-PRED EYE DROPS 1 % 5 ML x 1 | ALCON | Drops | 5 | 85,626 | 8.70 | 4,280,711 | 4.05% | 1.74 | -- |
-- |
|
| 2 | PRED FORTE OPHTH.SUSP. 1 % 10 ML x 1 | ALLERGAN | Drops | 10 | 1,114,318 | 74.39 | 82,894,102 | 78.51% | 7.44 | -- |
-- |
|
| 3 | PREDNISOLONE ACET. OPHTH.SUSP. 1 % 10 ML x | ALLERGAN | Drops | 10 | 2,443 | 13.20 | 32,248 | 0.03% | 1.32 | -- |
-- |
|
| 4 | PREDLY 1% EYE DROPS 5 ML | INDSWIFT LABORATORIES LTD. | Drops | 5 | 1,757 | 8.70 | 57,416 | 0.05% | 1.74 | -- |
-- |
|
| 5 | RENISONE EYE DROPS 1 % 5 ML x 1 | INTAS | Drops | 5 | 975 | 8.70 | 22,893 | 0.02% | 1.74 | -- |
-- |
|
| 6 | PRESOLON EYE DROPS 1 % 5 ML x 1 | KLAR SEHEN | Drops | 5 | 14,038 | 8.70 | 356,988 | 0.34% | 1.74 | -- |
-- |
|
| 7 | NAYANPRED EYE DROPS 1 % 5 ML x 1 | KLAR SEHEN | Drops | 5 | 858 | 8.70 | 17,538 | 0.02% | 1.74 | -- |
-- |
|
| 8 | PREDACE EYE DROPS 1 % 5 ML x 1 | MICRO LABS | Drops | 5 | 10,376 | 8.70 | 250,996 | 0.24% | 1.74 | -- |
-- |
|
| 9 | PDN EYE DROPS 1 % 5 ML x 1 | OPTHO REMEDIES | Drops | 5 | 3,628 | 8.70 | 99,951 | 0.09% | 1.74 | -- |
-- |
|
| 10 | PREDMET OPHTH.SUSP. 1 % 5 ML x 1 | SUN PHARMA | Drops | 5 | 352,769 | 8.70 | 11,228,642 | 10.63% | 1.74 | -- |
-- |
|
| 11 | PREDMET OPHTH.SUSP. 1 % 10 ML x 1 | SUN PHARMA | Drops | 10 | 460,383 | 13.74 | 6,325,383 | 5.99% | 1.37 | -- |
-- |
|
| 12 | PREDNIN-A OPHTH.SOLUT 1 % 5 ML x 1 | SUNWAYS | Drops | 5 | 620 | 8.70 | 16,691 | 0.02% | 1.74 | -- |
-- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
105,583,559 | 100.00% | 2.72 | 3.16 | -- |
|
-- |
Maximum | 7.44 | Minimum | 1.32 | -- |
|||||||
-- |
As per the above there are 3 companies consisting of Market Share of 1% & Above | -- |
-- |
-- |
-- |
-- |
-- |
-- |
||||
-- |
Sum of MAT value considered for price calculation | -- |
1047.61 | (Rs. in Lakhs) | -- |
-- |
||||||
-- |
Sum of PTR per unit considered for price calculation | -- |
13.61 | -- |
-- |
-- |
-- |
|||||
-- |
Number of Packs considered | -- |
-- |
5.00 | -- |
-- |
-- |
-- |
||||
-- |
Ceiling Price | -- |
-- |
2.72 | -- |
-- |
-- |
-- |
||||
-- |
Add : 16% Retailer Margin | -- |
-- |
0.44 | -- |
-- |
-- |
-- |
||||
-- |
MRP (without local taxes) | -- |
-- |
3.16 | -- |
-- |
-- |
-- |
||||
-- |
% Reduction with compared to Highest Price | -- |
-- |
63.41% | -- |
-- |
-- |
-- |
||||
-- |
WPI factor @ 6.32% | -- |
-- |
-- |
0.2 | -- |
-- |
-- |
||||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
-- |
3.36 | S.O. 2360( | -- |
-- |
-- |
||||
| Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Company | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit | Ceiling Price with 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.1.5. | Famotidine Tablets 20 mg | ACICON FILM C.TABS 20 MG x 14 | ACICON | ALEMBIC | 20 | 14 | TABS | 1285723 | 1.62% | 2.50 | 0.18 | -- |
-- |
Famotidine Tablets 20 mg | FACID FILM C.TABS 20 MG x 14 | FACID | INTAS PHA | 20 | 14 | TABS | 2564249 | 3.23% | 2.38 | 0.17 | -- |
-- |
Famotidine Tablets 20 mg | FADINE TAB UNCOATED 20 MG x 14 | FADINE | ARISTO PH | 20 | 14 | TABS | 7173977 | 9.03% | 1.73 | 0.12 | -- |
-- |
Famotidine Tablets 20 mg | FAMOCID FILM C.TABS 20 MG x 14 | FAMOCID | SUN* | 20 | 14 | TABS | 21985123 | 27.68% | 2.66 | 0.19 | -- |
-- |
Famotidine Tablets 20 mg | FAMONEXT TAB UNCOATED 20 MG x 14 | FAMONEXT | CADILA PH | 20 | 14 | TABS | 1612777 | 2.03% | 2.50 | 0.18 | -- |
-- |
Famotidine Tablets 20 mg | FAMOTIDINE TABS 20 MG x 14 | FAMOTIDINE | CADILA PH | 20 | 14 | TABS | 77466 | 0.10% | 2.45 | 0.18 | -- |
-- |
Famotidine Tablets 20 mg | FAMTAC TAB GELA.COA 20 MG x 14 | FAMTAC | ABBOTT* | 20 | 14 | TABS | 10700000 | 13.47% | 9.31 | 0.67 | -- |
-- |
Famotidine Tablets 20 mg | FM TAB UNCOATED 20 MG x 14 | FM | CAPLET IN | 20 | 14 | TABS | 1698864 | 2.14% | 2.50 | 0.18 | -- |
-- |
Famotidine Tablets 20 mg | TOPCID FILM C.TABS 20 MG x 14 | TOPCID | TORRENT | 20 | 14 | TABS | 32339973 | 40.71% | 2.62 | 0.19 | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
79438152 | 100.00% | -- |
0.23 | 0.27 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
maximum | 0.67 | minimum | 0.12 | -- |
-- |
As per the above there are 8 companies consisting of Market Share of 1 % & above | -- |
-- |
-- |
||||||||
-- |
Sum of MAT value considered for price calculation | 794.38 | (Rs. in lakhs) | -- |
-- |
-- |
-- |
|||||
-- |
Sum of PTR per unit considered for price calculation | 2.06 | -- |
-- |
-- |
-- |
-- |
|||||
-- |
Number of Packs considered | 9 | -- |
-- |
-- |
-- |
-- |
|||||
-- |
Average PTR | 0.23 | -- |
-- |
-- |
-- |
-- |
|||||
-- |
Add : 16% Retailer Margin | 0.04 | -- |
-- |
-- |
-- |
-- |
|||||
-- |
Ceiling price | 0.27 | -- |
-- |
-- |
-- |
-- |
|||||
-- |
% Reduction with compared to Highest Price | 65.67% | -- |
-- |
-- |
-- |
-- |
|||||
-- |
-- |
-- |
-- |
|||||||||
-- |
WPI increase on 1 April, 2014 | 6.32% | -- |
|||||||||
-- |
Ceiling Price after WPI Adjustment | 0.29 | S.O. 2366(E) dt. 15.9.2014 | -- |
||||||||
| Source of Data-Companies data July, 2013 | ||||||||||||
| S.No. | Composition of the Product | Brand Name | Company | Dosage Form | Pack size | Price to Retailer (Rs.) | MAT Value | MAT % | Price per tablet | Retail Price with 16 % Margin | – | |
| 1 | Azibact-CF Each film coated tablet contains: Cefpodoxime Proxetil Eq. to Cefpodoxime IP 200 mg Azithromycin Dihydrate Eq. to Azithromycin Anhydrous IP 250 mg q.s Excipients Approved Colour used |
GUDCEF -AZ Tablet | Lifestar Pharma Private Ltd. | Tablet | 10 | 152.38 | 68,000,000 | 23.27% | 15.24 | -- |
-- |
|
-- |
Kefpod-AZ 250 mg | Glenmark Pharmaceuticals Limited | Tablet | 10 | 151.62 | 65,323,000 | 22.36% | 15.16 | -- |
-- |
||
-- |
Macpod AZ | Macleods Pharmaceuticals Limited | Tablet | 10 | 153.21 | 71,100,000 | 24.33% | 15.32 | -- |
-- |
||
-- |
Zedocef AZ | Macleods Pharmaceuticals Limited | Tablet | 10 | 153.21 | 29,600,000 | 10.13% | 15.32 | -- |
-- |
||
-- |
GUDCEF -AZ Tablet | Mankind Pharmaceuticals ltd. | Tablet | 10 | 152.38 | 57,788,134 | 19.78% | 15.24 | -- |
-- |
||
-- |
-- |
-- |
Hetero Healthcare Ltd. | Tablet | 10 | 153.21 | 376,437 | 0.13% | 15.32 | -- |
-- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
292,187,571 | 100.00% | 15.26 | 17.70 | -- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Maximum | 15.32 | Minimum | 15.16 | -- |
|
-- |
As per the above there are 4 companies c | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|
-- |
Sum of MAT value considered for price cal | -- |
-- |
-- |
-- |
2918.11 | (Rs. in Lakhs) | -- |
-- |
-- |
-- |
|
-- |
Sum of PTR per unit considered for price c | -- |
-- |
-- |
-- |
76.28 | -- |
-- |
-- |
-- |
-- |
|
-- |
Number of Packs considered | -- |
-- |
-- |
-- |
5 | -- |
-- |
-- |
-- |
-- |
|
-- |
Average PTR | -- |
-- |
-- |
-- |
15.26 | -- |
-- |
-- |
-- |
-- |
|
-- |
Add : 16% Retailer Margin | -- |
-- |
-- |
-- |
2.44 | -- |
-- |
-- |
-- |
-- |
|
-- |
MRP (without local taxes) | -- |
-- |
-- |
-- |
17.70 | S.O. 2361(E) dt. | -- |
-- |
-- |
-- |
|
-- |
% Reduction with compared to Highest Pri | -- |
-- |
-- |
-- |
0.39% | -- |
-- |
-- |
-- |
-- |
|
| Source of Data-IMS( Dec, 2013) | ||||||||||||
| S.No. | Composition of the Product | Brand Name | Company | Dosage Form | Pack size | Price to Retailer (Rs.) | MAT Value | MAT % | Price per tablet | – | ||
| 1 | Metformin HCL SR Tablets Each uncoated sustained release tablet contains: Metformin Hydrochloride IP 750 mg |
-- |
Strides Arcolab | Tablet | 30 | 87.20 | 2,180 | 0.96% | 2.91 | -- |
||
-- |
Monopoly situation as only M/s. Str | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
||
-- |
PTR per unit | -- |
-- |
2.91 | -- |
-- |
-- |
-- |
-- |
-- |
||
-- |
Price fixed in the relevant sub-secti | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
||
-- |
18.5: Medicines used in Diabetes mellitus | -- |
-- |
-- |
-- |
-- |
||||||
-- |
18.5.1: Insulins and other Antidiabetic agents | -- |
-- |
-- |
-- |
-- |
||||||
| S.No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price | – | ||
| 1 | Metformin | P, S, T | Tablets | 500 mg | 1.56 | 2nd | 1814 | 21.6.2013 | 41.56 | -- |
||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction | 41.56 | -- |
||
-- |
Therefore, PTR per unit | -- |
-- |
2.91x(1-41.56%) | 1.70 | -- |
-- |
-- |
-- |
-- |
||
-- |
Add: 16% Retailer Margin | -- |
-- |
-- |
0.27 | -- |
-- |
-- |
-- |
-- |
||
-- |
Retail Price per unit | -- |
-- |
-- |
1.97 | S.O. 2363( | -- |
-- |
-- |
-- |
||
| Source of Data-Pharma Trac data Dec, 2013 | ||||||||||||
| S.No. | Composition of the Product | Brand Name | Company | Dosage Form | Pack size | Price to Retailer (Rs.) | MAT Value | MAT % | Price per capsule | – | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Parvon -Spas Plus Each capsule contains: Tramadol Hydrochloride IP 50 mg, Dicyclomine Hydrochloride IP 10 mg, Acetaminophen IP 325 mg |
Spasmo Proxyvon Plus | Wockhardt Ltd. | Capsule | 8 | 24.37 | 281,807,978 | 100.00% | 3.05 | -- |
||
-- |
Monopoly situation as only M/s. Wockhardt is t | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
||
-- |
PTR per unit | -- |
-- |
3.05 | -- |
-- |
-- |
-- |
-- |
-- |
||
-- |
Price fixed in the relevant sub-section for oth | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
||
-- |
Section: 2 – Analgesics , Antipyretics, Nonsteroidal Anti-inflammatory Medicines, Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders | -- |
-- |
-- |
-- |
|||||||
-- |
2.1: Non-Opioid Analgesics, Antipyretics and Nonsteroidal Anti-inflammatory Medicines | -- |
-- |
-- |
-- |
|||||||
| – | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price | – | ||
-- |
Paracetamol | P, S, T | Injection | 150 mg/ml | 3.43 | 9th | 3567(E) | 02.12.2013 | 22.31% | -- |
||
-- |
Paracetamol | P, S, T | Syrup | 125 mg / 5ml | 0.32 | 11th | 421(E) | 17.02.2014 | 30.00% | -- |
||
-- |
Paracetamol | P, S, T | Tablets | 500 mg | 0.94 | 1st | 1555(E) | 14.6.2013 | 56.97% | -- |
||
-- |
Paracetamol | P, S, T | Suppository | 80 mg | 6.96 | 9th | 3568(E) | 02.12.2013 | 28.45% | -- |
||
-- |
Paracetamol | P, S, T | Suppository | 170 mg | 8.07 | 9th | 3569(E) | 02.12.2013 | 16.98% | -- |
||
-- |
Added medicines | -- |
-- |
-- |
-- |
-- |
-- |
|||||
-- |
Tramadol | S,T | Capsule | 50 mg | 6.03 | 16th | 1788(E) | 10.07.2014 | 26.24% | -- |
||
-- |
17.4: Antispasmodic medicines | -- |
-- |
-- |
||||||||
-- |
Dicyclomine Hydrochloride | P,S,T | Tablets | 10 mg | No Data | -- |
-- |
-- |
-- |
-- |
||
-- |
Dicyclomine Hydrochloride | P,S,T | Injection | 10 mg/ml | 2.95 | 4th | 2064(E) | 05.07.2013 | 65.44% | -- |
||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction | 35.20% | -- |
||
-- |
Therefore, PTR per unit | 3.05 X (1-35.20%) | 1.98 | -- |
-- |
|||||||
-- |
Add: 16% Retailer Margin | -- |
0.32 | -- |
-- |
|||||||
-- |
Retail Price per unit | -- |
2.30 | S.O. 2364(E) dt. 15.9.2014 | -- |
-- |
||||||
Source of Data-Company ( Sep, 2013)
| S.No. | Composition of the Product | Brand Name | Company | Dosage Form | Pack size | Price to Retailer (Rs.) | MAT Value | MAT % | Price per tablet |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Each uncoated bilayered tablet contains: Glimepiride IP 0.5 mg Metformin Hydrochloride IP 500 mg (As extended release form) |
Glycomet GP 0.5 | USV Limited | Tablet | 10 | 34.17 | 55,700,000 | 16327.27% | 3.42 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
55,700,000 | 16327.27% | 0.31 |
-- |
Monopoly situation as only M/s. | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
PTR per unit | -- |
-- |
3.42 | -- |
-- |
-- |
-- |
-- |
-- |
Price fixed in the relevant sub-s | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
18.5: Medicines used in Diabetes mellitus | -- |
|||||||
-- |
18.5.1: Insulins and other Antidiabetic agents | -- |
|||||||
| S>No. | Medicines | Category | Route of Administration/ Dosage Form | Strengths | Unit Ceiling Price (Rs.) | Meeting No. | S.O. No. | Date | % Reduction w.r.t. Highest Price |
| 1 | Metformin | P,S,T | Tablets | 500mg | 1.56 | 2nd | 1814 | 21.6.2013 | 41.56 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction | 41.56 | |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Therefore, PTR per unit | 3.42x(1-41.56%) | 2.00 | -- |
-- |
-- |
-- |
||
-- |
Add: 16% Retailer Margin | -- |
0.32 | -- |
-- |
-- |
-- |
||
-- |
Retail Price per unit | -- |
2.32 | S.O. 2365( | -- |
-- |
-- |
||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3.0.6.1 | Pheniramine Maleate Injection 22.75 mg / ml | AVIL INJ AMP 22.7 MG 2 ML x 10 (/1ML) | AVIL | 22.7 | 20 | ML | 220174 | 0.12% | 28.93 | 1.45 |
-- |
-- |
Pheniramine Maleate Injection 22.75 mg / ml | AVIL INJ AMP 22.7 MG 2 ML x 1 (/1ML) | AVIL | 22.7 | 2 | ML | 75544237 | 40.28% | 2.91 | 1.46 |
-- |
-- |
Pheniramine Maleate Injection 22.75 mg / ml | AVIL INJ VIAL 22.7 MG 10 ML x 1 (/1ML) | AVIL | 22.7 | 10 | ML | 111379608 | 59.39% | 8.27 | 0.83 |
-- |
-- |
Pheniramine Maleate Injection 22.75 mg / ml | INTAVIL INJ AMP 22.7 MG 2 ML x 1 (/1ML) | INTAVIL | 22.7 | 2 | ML | 409121 | 0.22% | 2.56 | 1.28 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
187553140 | -- |
-- |
-- |
-- |
-- |
Monopoly situation as M/s Sanofi is the only company manufacturing the formulation and has market share of 99.78% | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
Average PTR per unit | -- |
1.25 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||||
-- |
Section: 3 – Antiallergics and Medicines used in Anaphylaxis | -- |
-- |
-- |
-- |
||||||
-- |
Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | -- |
||
-- |
Adrenaline Bitartrate | P, S, T | Injection | 37.24 | 1st | 1565 | 14.06.2013 | 48.32% | -- |
||
-- |
Chlorpheniramine Maleate | P, S, T | Tablets | 0.10 | 5th | 2232 | 22.07.2013 | 76.21% | -- |
||
-- |
Dexchlorpheniramine Maleate | P, S, T | Syrup | 0.30 | 7th | 2831 | 20.09.2013 | 44.86% | -- |
||
-- |
Dexamethasone | P, S, T | Tablets | 0.19 | 14th | 1157 | 28.04.2014 | 11.11% | -- |
||
-- |
Dexamethasone | P, S, T | Injection | 2.51 | 14th | 1157 | 28.04.2014 | 38.81% | -- |
||
-- |
Hydrocortisone Sodium Succinate | P, S, T | Injection | 37.13 | 5th | 2233 | 22.07.2013 | 44.72% | -- |
||
-- |
Pheniramine Maleate | P, S, T | Injection | Monopoly | -- |
-- |
-- |
-- |
-- |
||
-- |
Prednisolone | P, S, T | Tablets | 0.55 | 13th | 1008 | 02.04.2014 | 2.08% | -- |
||
-- |
Prednisolone | P, S, T | Tablets | 0.92 | 13th | 1009 | 02.04.2014 | 4.82% | -- |
||
-- |
Prednisolone | P, S, T | Tablets | 1.72 | 12th | 947 | 27.03.2014 | 0.00% | -- |
||
-- |
Promethazine | P, S, T | Tablets | 0.93 | 7th | 2832 | 20.09.2013 | 28.00% | -- |
||
-- |
Promethazine | P, S, T | Tablets | 2.49 | 1st | 1566 | 14.06.2013 | 12.70% | -- |
||
-- |
Promethazine | P, S, T | Syrup/Elixir | 0.21 | 1st | 1552 | 14.06.2013 | 43.30% | -- |
||
-- |
Added Medicines | -- |
-- |
-- |
-- |
||||||
-- |
Cetrizine | P, S, T | Tablets | 1.81 | 3rd | 1875 | 28.06.2013 | 49.14% | -- |
||
-- |
Cetrizine | P, S, T | Syrup | 0.54 | 3rd | 1876 | 28.06.2013 | 56.48% | -- |
||
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction% | 32.90% | -- |
|||
-- |
Therefore, PTR per unit | 1.25 X (1-32.90%) | 0.84 | -- |
-- |
-- |
-- |
||||
-- |
Add: 16% Retailer Margin | -- |
0.13 | -- |
-- |
-- |
-- |
||||
-- |
Ceiling Price per unit | -- |
0.97 | -- |
-- |
-- |
-- |
||||
-- |
WPI factor @ 6.32% | -- |
0.06 | -- |
-- |
-- |
-- |
||||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
1.03 | S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
|||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
13.2.0.7 | Silver Sulphadiazine Cream 1% | SILVEZ CREAM 1 % 20 G x 1 | SILVEZ | 1 | 20 | G | 1041855 | 99.90% | 7.53 | 0.38 |
-- |
-- |
Silver Sulphadiazine Cream 1% | SILVA 1% CREAM 20 G | SILVA | 1 | 20 | G | 180 | 0.02% | 7.60 | 0.38 |
-- |
-- |
Silver Sulphadiazine Cream 1% | SILVERINE 1% CREAM 20 G | SILVERINE | 1 | 20 | G | 826 | 0.08% | 7.60 | 0.38 |
-- |
-- |
-- |
-- |
-- |
-- |
1042861 | 100.00% | Average | 0.38 | ||
-- |
-- |
Monopoly situation as M/s LABORATE PHARMA is the only company manufacturing the formulation and h | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
PTR per unit | -- |
0.38 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
13.2: Antiinfective medicines | -- |
-- |
-- |
-- |
-- |
-- |
|||
| – | – | Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | – | |
-- |
-- |
Acyclovir | S, T | Cream | 8.88 | 2nd | 1812 | 21.06.2013 | 34.22% | -- |
|
-- |
-- |
Framycetin Sulphate | P,S,T | Cream | Data not yet avaibale | -- |
-- |
-- |
-- |
-- |
|
-- |
-- |
Methylrosanilinium Chloride (Gentian Violet) | P,S,T | Aqueous solution | Data not yet available | -- |
-- |
-- |
-- |
-- |
|
-- |
-- |
Neomycin + Bacitracin | P,S,T | Ointment | 0.85 | 17th | 2087 | 20.08.2014 | 53.75% | -- |
|
-- |
-- |
Povidone Iodine | P,S,T | Solution | 0.39 | 1st | 1651 | 14.06.2013 | 69.14% | -- |
|
-- |
-- |
Povidone Iodine | P,S,T | Ointment | 1.64 | 3rd | 1905 | 28.06.2013 | 57.89% | -- |
|
-- |
-- |
Silver Sulphadiazine | P,S,T | Cream | Monopoly | -- |
-- |
-- |
-- |
-- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction | -- |
53.75% | -- |
|
-- |
-- |
Therefore, PTR per unit | 0.38 X (1-53.75%) | 0.18 | -- |
-- |
-- |
-- |
-- |
||
-- |
-- |
Add: 16% Retailer Margin | -- |
0.03 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Ceiling Price per unit | -- |
0.21 | -- |
-- |
-- |
-- |
|||
-- |
WPI factor @ 6.32% | -- |
0.01 | -- |
-- |
-- |
-- |
||||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
0.22 | S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
|||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
12.2.13.0 | Verapamil Tablets 40mg | CALAPTIN FILM C.TABS 40 MG x 10 | CALAPTIN | 40 | 10 | TABS | 45248924 | 100.00% | 5.7 | 0.57 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
45248924 | -- |
-- |
-- |
-- |
-- |
Monopoly situation as M/s Abbott is the only company manufacturing the formulation and has market share of 100% | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
PTR per unit | -- |
0.57 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
12.2: Antiarrhythmic medicines | -- |
-- |
-- |
-- |
-- |
||||
| – | – | Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | – | – |
-- |
-- |
Adenosine | S,T | Injection | 114.55 | 1st | 1627 | 14.06.2013 | 39.69% | -- |
-- |
-- |
-- |
Amiodarone | S,T | Tablets | 6.52 | 1st | 1628 | 14.06.2013 | 16.99% | -- |
-- |
-- |
-- |
Amiodarone | S,T | Tablets | 11.67 | 1st | 1629 | 14.06.2013 | 20.76% | -- |
-- |
-- |
-- |
Amiodarone | S,T | Injection | 20.76 | 1st | 1630 | 14.06.2013 | 23.31% | -- |
-- |
-- |
-- |
Diltiazem | S,T | Tablets | 2.27 | 1st | 1622 | 14.06.2013 | 33.04% | -- |
-- |
-- |
-- |
Diltiazem | S,T | Tablets | 4.79 | 3rd | 1899 | 28.06.2013 | 46.47% | -- |
-- |
-- |
-- |
Diltiazem | T | Injection | 3.02 | 7th | 2843 | 20.09.2013 | 39.75% | -- |
-- |
-- |
-- |
Esmolol | T | Injection | 20.51 | 1st | 1631 | 14.06.2013 | 11.59% | -- |
-- |
-- |
-- |
Lignocaine Hydrochloride | S,T | Injection | 6.87 | 8th | 3376 | 05.11.2013 | 49.41% | -- |
-- |
-- |
-- |
Lignocaine Hydrochloride | S,T | Injection | 1.00 | 5th | 2248 | 22.07.2013 | 49.41% | -- |
-- |
-- |
-- |
Procainamide Hydrochloride | T | Tablets | Data not available | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Procainamide Hydrochloride | T | Injection | Data not yet available | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Verapamil | S,T | Tablets | Monopoly | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Verapamil | S,T | Tablets | Monopoly | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Verapamil | S,T | Injection | Monopoly | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction% | 33.04% | -- |
-- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||
-- |
-- |
Therefore, PTR per unit | 0.57X (1-33.04%) | 0.38 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Add: 16% Retailer Margin | -- |
0.06 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Ceiling Price per unit | -- |
0.44 | -- |
-- |
-- |
-- |
|||
-- |
-- |
WPI factor @ 6.32% | -- |
0.03 | -- |
-- |
-- |
-- |
|||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
0.47 | S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
|||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
12.2.14.0 | Verapamil Tablets 80 mg | CALAPTIN FILM C.TABS 80 MG x 10 | CALAPTIN | 80 | 10 | TABS | 11735709 | 100.00% | 10.9 | 1.09 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
11735709 | -- |
-- |
-- |
-- |
-- |
Monopoly situation as M/s Abbott is the only company manufacturing the formulation and has market share of 100% | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
PTR per unit | -- |
1.09 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
12.2: Antiarrhythmic medicines | -- |
-- |
-- |
-- |
-- |
||||
| – | – | Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | – | – |
-- |
-- |
Adenosine | S,T | Injection | 114.55 | 1st | 1627 | 14.06.2013 | 39.69% | -- |
-- |
-- |
-- |
Amiodarone | S,T | Tablets | 6.52 | 1st | 1628 | 14.06.2013 | 16.99% | -- |
-- |
-- |
-- |
Amiodarone | S,T | Tablets | 11.67 | 1st | 1629 | 14.06.2013 | 20.76% | -- |
-- |
-- |
-- |
Amiodarone | S,T | Injection | 20.76 | 1st | 1630 | 14.06.2013 | 23.31% | -- |
-- |
-- |
-- |
Diltiazem | S,T | Tablets | 2.27 | 1st | 1622 | 14.06.2013 | 33.04% | -- |
-- |
-- |
-- |
Diltiazem | S,T | Tablets | 4.79 | 3rd | 1899 | 28.06.2013 | 46.47% | -- |
-- |
-- |
-- |
Diltiazem | T | Injection | 3.02 | 7th | 2843 | 20.09.2013 | 39.75% | -- |
-- |
-- |
-- |
Esmolol | T | Injection | 20.51 | 1st | 1631 | 14.06.2013 | 11.59% | -- |
-- |
-- |
-- |
Lignocaine Hydrochloride | S,T | Injection | 6.87 | 8th | 3376 | 05.11.2013 | 49.41% | -- |
-- |
-- |
-- |
Lignocaine Hydrochloride | S,T | Injection | 1.00 | 5th | 2248 | 22.07.2013 | 49.41% | -- |
-- |
-- |
-- |
Procainamide Hydrochloride | T | Tablets | Data not available | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Procainamide Hydrochloride | T | Injection | Data not yet available | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Verapamil | S,T | Tablets | 0.46 | Proposed for 18th AM | -- |
-- |
33.04% | -- |
-- |
-- |
-- |
Verapamil | S,T | Tablets | Monopoly Item | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Verapamil | S,T | Injection | Under consideration | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction% | 33.04% | -- |
-- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||
-- |
-- |
Therefore, PTR per unit | 1.09 X (1-33.04%) | 0.73 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Add: 16% Retailer Margin | -- |
0.12 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Ceiling Price per unit | -- |
0.85 | -- |
-- |
-- |
-- |
|||
-- |
WPI factor @ 6.32% | -- |
0.05 | -- |
-- |
-- |
-- |
||||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
0.90 | S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
|||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
12.2.15.0 | Verapamil Injection 2.5mg/ml | VPL INJ AMP 2.50 MG 2 ML x 1 (/1ML) | VPL | 2.5 MG | 2 | ML | 20696 | 100.00% | 1.76 | 0.88 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
20696 | -- |
-- |
-- |
-- |
-- |
Monopoly situation as M/s Samarth Pharma is the only company manufacturing the formulation and has market share of 100% | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
PTR per unit | -- |
0.88 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
12.2: Antiarrhythmic medicines | -- |
-- |
-- |
-- |
-- |
||||
| – | – | Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | – | – |
-- |
-- |
Adenosine | S,T | Injection | 114.55 | 1st | 1627 | 14.06.2013 | 39.69% | -- |
-- |
-- |
-- |
Amiodarone | S,T | Tablets | 6.52 | 1st | 1628 | 14.06.2013 | 16.99% | -- |
-- |
-- |
-- |
Amiodarone | S,T | Tablets | 11.67 | 1st | 1629 | 14.06.2013 | 20.76% | -- |
-- |
-- |
-- |
Amiodarone | S,T | Injection | 20.76 | 1st | 1630 | 14.06.2013 | 23.31% | -- |
-- |
-- |
-- |
Diltiazem | S,T | Tablets | 2.27 | 1st | 1622 | 14.06.2013 | 33.04% | -- |
-- |
-- |
-- |
Diltiazem | S,T | Tablets | 4.79 | 3rd | 1899 | 28.06.2013 | 46.47% | -- |
-- |
-- |
-- |
Diltiazem | T | Injection | 3.02 | 7th | 2843 | 20.09.2013 | 39.75% | -- |
-- |
-- |
-- |
Esmolol | T | Injection | 20.51 | 1st | 1631 | 14.06.2013 | 11.59% | -- |
-- |
-- |
-- |
Lignocaine Hydrochloride | S,T | Injection | 6.87 | 8th | 3376 | 05.11.2013 | 49.41% | -- |
-- |
-- |
-- |
Lignocaine Hydrochloride | S,T | Injection | 1.00 | 5th | 2248 | 22.07.2013 | 49.41% | -- |
-- |
-- |
-- |
Procainamide Hydrochloride | T | Tablets | Data not available | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Procainamide Hydrochloride | T | Injection | Data not available | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Verapamil | S,T | Tablets | 0.44 | Proposed for 18th AM | 33.04% | -- |
-- |
||
-- |
-- |
Verapamil | S,T | Tablets | 0.85 | Proposed for 18th AM | 33.04% | -- |
-- |
||
-- |
-- |
Verapamil | S,T | Injection | Under Consideration | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction% | 33.04% | -- |
-- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||
-- |
-- |
Therefore, PTR per unit | 0.88 X (1-33.04%) | 0.59 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Add: 16% Retailer Margin | -- |
0.09 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Ceiling Price per unit | -- |
0.68 | -- |
-- |
-- |
-- |
|||
-- |
WPI factor @ 6.32% | -- |
0.04 | -- |
-- |
-- |
-- |
||||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
0.72 | S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
|||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
2.1.0.1 | Acetyl Salicylic Acid Tablets 325 mg | ECOSPRIN ENTER C.TABS 325 MG x 14 | ECOSPRIN | 325 | 14 | TABS | 8048948 | 100.00% | 7.58 | 0.54 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
8048948 | -- |
-- |
-- |
-- |
-- |
Monopoly situation as M/s USV is the only company manufacturing the formulation and has market share of 100% | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
PTR per unit | -- |
0.54 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
2.1: Non-Opioid Analgesics, Antipyretics and Nonsteroidal Anti-inflammatory Medicines | -- |
-- |
-- |
||||||
| – | – | – | Medicines | Category | Strengths | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | – |
-- |
-- |
1 | Acetyl Salicylic Acid | P, S, T | 325 mg | Under consideration | -- |
-- |
-- |
-- |
-- |
-- |
-- |
2 | Acetyl Salicylic Acid | 350 mg | Data not available | -- |
-- |
-- |
-- |
-- |
|
-- |
-- |
3 | Diclofenac | T | 50 mg | 1.95 | 3rd | 1909 | 28.06.2013 | 52.64% | -- |
-- |
-- |
4 | Diclofenac | T | 25 mg / ml | 1.49 | 7th | 2869 | 20.09.2013 | 70.44% | -- |
-- |
-- |
5 | Ibuprofen | P, S, T | 200 mg | Price Notified in Dec 2013 under DPCO, 1995 in 10th Meeting will be notified in April 2015 | -- |
-- |
|||
-- |
-- |
6 | Ibuprofen | 400 mg | Price Notified in Dec 2013 under DPCO, 1995 in 10th Meeting will be notified in April 2015 | -- |
-- |
||||
-- |
-- |
7 | Ibuprofen | 100mg/5ml | 0.21 | 12th | 946 | 27.03.2014 | 0.00% | -- |
|
-- |
-- |
8 | Paracetamol | P, S, T | 150 mg / ml | 3.43 | 9th | 3567 | 02.12.2013 | 22.31% | -- |
-- |
-- |
9 | Paracetamol | P, S, T | 125 mg / 5ml | 0.32 | 11th | 421 | 17.02.2014 | 30.00% | -- |
-- |
-- |
10 | Paracetamol | P, S, T | 500 mg | 0.94 | 1st | 1555 | 14.06.2013 | 56.97% | -- |
-- |
-- |
11 | Paracetamol | P, S, T | 80 mg | 6.96 | 9th | 3568 | 02.12.2013 | 28.45% | -- |
-- |
-- |
12 | Paracetamol | P, S, T | 170 mg | 8.07 | 9th | 3569 | 02.12.2013 | 16.98% | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction% | 34.72% | -- |
|
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||
-- |
-- |
Therefore, PTR per unit | 0.54 X (1-34.72%) | 0.35 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Add: 16% Retailer Margin | -- |
0.06 | -- |
-- |
-- |
-- |
-- |
||
-- |
-- |
Ceiling Price per unit | -- |
0.41 | -- |
-- |
-- |
-- |
|||
-- |
WPI factor @ 6.32% | -- |
0.03 | -- |
-- |
-- |
-- |
-- |
-- |
||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
0.44 | S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
-- |
-- |
|
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
8.3.0.2 | Prednisolone Injection 20 mg | OMNACORTIL INJ AMP 20 MG 2 ML x 1 (/1ML) | OMNACORTIL | 20 | 2 | ML | 133151 | 100.00% | 7.32 | 3.66 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
133151 | -- |
-- |
-- |
-- |
-- |
Monopoly situation as M/s Macleods Pharma is the only company manufacturing the formulation and has market share of 100% | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
PTR per unit | -- |
3.66 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
-- |
-- |
-- |
-- |
||||||
-- |
8.3: Hormones and antihormones | -- |
-- |
-- |
-- |
||||||
| — | Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | – | ||
-- |
Prednisolone | S, T | Tablets | 0.55 | 13th | 1008 | 02.04.2014 | 2.08% | -- |
||
-- |
Prednisolone | Injection | Under consideration | -- |
-- |
-- |
-- |
-- |
|||
-- |
Prednisolone | Injection | Data not available | -- |
-- |
-- |
-- |
-- |
|||
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction% | 2.08% | -- |
|||
-- |
-- |
-- |
-- |
-- |
-- |
||||||
-- |
Therefore, PTR per unit | 3.66 X (1-2.08%) | 3.58 | -- |
-- |
-- |
-- |
||||
-- |
Add: 16% Retailer Margin | -- |
0.57 | -- |
-- |
-- |
-- |
||||
-- |
Ceiling Price per unit | -- |
4.15 | -- |
-- |
-- |
-- |
||||
-- |
-- |
WPI factor @ 6.32% | -- |
0.26 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
4.41 | S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
6.2.2.4.1 & 6.5.4 |
Co-Trimoxazole (Trimethoprim + SulphamethoxaZole) Tablets 80 + 400 mg | ANTRIMA TABS 400 MG x 10 (/80) | ANTRIMA | 400/80 | 10 | TABS | 1039856 | 0.50% | 4.50 | 0.45 |
-- |
Co-Trimoxazole (Trimethoprim + SulphamethoxaZole) Tablets 80 + 400 mg | SEPTRAN TABS ADULT 400 MG x 10 (/80) | SEPTRAN | 400/80 | 10 | TABS | 207920398 | 99.50% | 5.04 | 0.50 | |
-- |
208960254 | 100.00% | -- |
-- |
|||||||
-- |
Monopoly situation as M/s GLAXOSMITHKLINE is the company manufacturing the formulation and has market share of 99.50% | -- |
-- |
-- |
|||||||
-- |
PTR per unit | -- |
0.50 | -- |
-- |
-- |
|||||
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
|||||||
-- |
-- |
Section: 6 – Anti-infective Medicines | -- |
-- |
-- |
-- |
|||||
-- |
-- |
6.2.2 Other Antibacterials | -- |
-- |
-- |
-- |
|||||
| – | Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | – | ||
-- |
Co-Trimoxazole (Trimethoprim + Sulphamethoxazole) | P,S,T | Tablets | Under consideration | -- |
-- |
-- |
-- |
-- |
||
-- |
Co-Trimoxazole (Trimethoprim + Sulphamethoxazole) | P,S,T | Tablets | 1.28 | 14th | 1157(E) | 28.04.2014 | 5.98% | -- |
||
-- |
Co-Trimoxazole (Trimethoprim + Sulphamethoxazole) | P,S,T | Suspension | 0.24 | 14th | 1157(E) | 28.04.2014 | 4.55% | -- |
||
-- |
Average Reduction | 5.27% | -- |
||||||||
-- |
-- |
-- |
|||||||||
-- |
Therefore, PTR per unit | 0.50 X (1-5.27%) | 0.47 | -- |
-- |
-- |
|||||
-- |
Add: 16% Retailer Margin | -- |
0.08 | -- |
-- |
-- |
|||||
-- |
Ceiling Price per unit | -- |
0.55 | -- |
-- |
-- |
|||||
-- |
WPI factor @ 6.32% | -- |
0.03 | -- |
-- |
-- |
|||||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
0.58 | S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
||||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.1.1.1 | Aluminium Hydroxide+Magnesium Hydroxide | GELUSIL TABLET 10 | -- |
PFIZER LTD | 10 | Tablet | 18048180 | 76.41% | 7.72 | 0.77 | -- |
-- |
Aluminium Hydroxide+Magnesium Hydroxide | GELUSIL TABLET 8 | -- |
PFIZER LTD | 8 | Tablet | 25130 | 0.11% | 7.79 | 0.97 | -- |
-- |
Aluminium Hydroxide+Magnesium Hydroxide | GELUSIL XTRACOOL BLUE 50/250 MG TABLET 10 | -- |
PFIZER LTD | 10 | Tablet | 5546806 | 23.48% | 7.67 | 0.77 | -- |
-- |
-- |
-- |
-- |
23620117 | 100.00% | -- |
0.84 | -- |
|||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||
-- |
Monopoly situation as M/s Pfizer Ltd is the company manufacturing the formulation and has market share of 100% | -- |
-- |
-- |
-- |
-- |
-- |
-- |
|||
-- |
PTR per unit | -- |
0.84 | -- |
-- |
-- |
-- |
||||
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
||||||
-- |
-- |
-- |
|||||||||
-- |
Section: 17 – Gastrointestinal medicines | -- |
-- |
-- |
-- |
||||||
-- |
17.1: Antacids and other Antiulcer medicines | -- |
-- |
-- |
-- |
||||||
| – | Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | – | ||
-- |
Aluminium Hydroxide + Magnesium Hydroxide | P,S,T | Tablet | -- |
-- |
-- |
-- |
-- |
-- |
||
-- |
Aluminium Hydroxide + Magnesium Hydroxide | Suspension | -- |
-- |
-- |
-- |
-- |
-- |
|||
-- |
Omeprazole | P,S,T | Capsules | 10 mg | 2nd | 1828 | 21.06.2013 | 30.50% | -- |
||
-- |
Omeprazole | Capsules | 20 mg | 2nd | 1829 | 21.06.2013 | 192.11% | -- |
|||
-- |
Omeprazole | Capsules | 40 mg | 8th | 3346 | 05.11.2013 | 17.16% | -- |
|||
-- |
Ranitidine | P,S,T | Injection | 25 mg / ml | 14th | 1157 | 28.04.2014 | 15.17% | -- |
||
-- |
Added Medicines | -- |
-- |
-- |
-- |
-- |
|||||
-- |
Pantoprazole | T | Injection | 40 mg | 16th | 1789 | 10.07.2014 | 31.57% | -- |
||
-- |
Famotidine | P,S,T | Tablets | 20 mg | 13th | 1016 | 02.04.2014 | 30.77% | -- |
||
-- |
Average Reduction | 52.88% | -- |
||||||||
-- |
Therefore, PTR per unit | 0.84 X (1-52.88%) | 0.40 | -- |
-- |
-- |
|||||
-- |
Add: 16% Retailer Margin | -- |
0.06 | -- |
-- |
-- |
|||||
-- |
Ceiling Price per unit | -- |
0.46 | -- |
-- |
-- |
-- |
-- |
|||
-- |
WPI factor @ 6.32% | -- |
0.03 | -- |
-- |
-- |
-- |
-- |
|||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
0.49 | -- |
S.O. 2355(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit | – |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
17.1.1.1 | Aluminium Hydroxide+Magnesium Hydroxide | ZEROCID MPS MINT SYRUP 170 ML | -- |
Not specified | SEAGULL | 170 | ML | 15528 | 9.80% | 12.00 | 0.07 |
-- |
17.1.1.1 | Aluminium Hydroxide+Magnesium Hydroxide | STABIGEL SUSPENSION 170 ML | -- |
Not specified | RHOMBUS | 170 | ML | 1441 | 0.91% | 41.16 | 0.24 |
-- |
17.1.1.1 | Aluminium Hydroxide+Magnesium Hydroxide | -- |
Manila | Not specified | Swiss India | 170 | ML | 35280 | 22.27% | 38.22 | 0.22 |
-- |
17.1.1.1 | Aluminium Hydroxide+Magnesium Hydroxide | -- |
Alocid | Not specified | Swiss India | 170 | ML | 54411 | 34.34% | 38.22 | 0.22 |
-- |
17.1.1.1 | Aluminium Hydroxide+Magnesium Hydroxide | -- |
Concid | Not specified | Swiss India | 170 | ML | 33495 | 21.14% | 38.22 | 0.22 |
-- |
17.1.1.1 | Aluminium Hydroxide+Magnesium Hydroxide | -- |
Ralcain | Not specified | Swiss India | 170 | ML | 18270 | 11.53% | 42.12 | 0.25 |
-- |
-- |
-- |
-- |
158425 | 100.00% | -- |
0.2 | |||||
-- |
-- |
-- |
-- |
-- |
maximum | 0.25 | minimum | |||||
-- |
As per the above there are 2 companies consisting of Market Share of 1% & Above | -- |
-- |
-- |
-- |
-- |
-- |
-- |
-- | |||
-- |
Sum of MAT value considered for price calculation | -- |
1.57 | (Rs. in Lakhs) | -- |
-- |
||||||
-- |
Sum of PTR per unit considered for price calculation | -- |
0.98 | -- |
-- |
-- |
-- |
|||||
-- |
Number of Packs considered | -- |
-- |
5 | -- |
-- |
-- |
-- |
||||
-- |
Ceiling Price | -- |
-- |
0.20 | -- |
-- |
-- |
-- |
||||
-- |
Add : 16% Retailer Margin | -- |
-- |
0.03 | -- |
-- |
-- |
-- |
||||
-- |
MRP (without local taxes) | -- |
-- |
0.23 | -- |
-- |
-- |
-- |
-- |
|||
-- |
% Reduction with compared to Highest Price | -- |
-- |
20.00% | -- |
-- |
-- |
-- |
-- |
|||
-- |
WPI factor @ 6.32% | -- |
-- |
0.01 | -- |
-- |
-- |
|||||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
-- |
0.24 | -- |
S.O. 2348(E) dt. 15.9.2014 | -- |
-- |
||||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
12.1.1.2 & 12.5.1.2 | Acetyl Salcylic Acid Tablet 100 mg | COLSPRIN(RECKITT) 100 MG TABLET 14X10 | -- |
100 MG | 140 | TABLET | 5001 | 100% | 16.80 | 0.12 |
-- |
Monopoly situation as M/s Reckitt Benckiser is the company manufacturing the formulation and has market share of 100% | -- |
-- |
-- |
-- |
||||||
-- |
PTR per unit | -- |
0.12 | -- |
-- |
-- |
-- |
-- |
|||
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
|||||
-- |
Section: 12 – Cardiovascular medicines | -- |
-- |
-- |
-- |
||||||
-- |
12.1 : Antianginal medicines & Section 12.5: Antithrombotic medicines | -- |
-- |
-- |
-- |
||||||
-- |
Medicines | Category | Route of Administration/ Dosage Form | Strengths | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | -- |
||
-- |
Acetyl salicylic acid | P,S,T | Tablets | 75 mg soulble/dispersible | 12th | 952(E) | 27.03.2014 | 8.33% | -- |
||
-- |
Acetyl salicylic acid | P,S,T | Tablets | 100 mg | -- |
-- |
-- |
-- |
-- |
||
-- |
Acetyl salicylic acid | P,S,T | Tablets | 350 mg | -- |
-- |
-- |
-- |
-- |
||
-- |
-- |
Average Reduction | 8.33% | -- |
|||||||
-- |
-- |
-- |
-- |
-- |
|||||||
-- |
Therefore, PTR per unit | 0.12 X (1-8.33%) | 0.11 | -- |
-- |
-- |
-- |
||||
-- |
Add: 16% Retailer Margin | -- |
0.02 | -- |
-- |
-- |
-- |
||||
-- |
Ceiling Price per unit | -- |
0.13 | -- |
-- |
-- |
-- |
||||
-- |
WPI factor @ 6.32% | -- |
0.01 | -- |
-- |
-- |
-- |
||||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
0.14 | -- |
S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
13.2.2.1 | Framycetin Sulphate Cream 0.5% | SOFRAMYCIN 0.5% CREAM 30 GM | -- |
0.005 | 30 | GM | 299353768 | 100% | 19.06 | 0.64 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
||||
-- |
Monopoly situation as M/s Sofi India Ltd. is the company manufacturing the formulation and has market share of 100% | -- |
-- |
-- |
-- |
||||||
-- |
PTR per unit | -- |
0.64 | -- |
-- |
-- |
-- |
-- |
|||
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
|||||
-- |
-- |
13.2: Antiinfective medicines | -- |
-- |
-- |
-- |
-- |
-- |
|||
-- |
Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | -- |
||
-- |
-- |
Acyclovir | S, T | Cream | 8.88 | 2nd | 1812 | 21.06.2013 | 34.22% | -- |
|
-- |
-- |
Framycetin Sulphate | P,S,T | Cream | Under consideration | -- |
-- |
-- |
-- |
-- |
|
-- |
-- |
Methylrosanilinium Chloride (Gentian Violet) | P,S,T | Aqueous solution | Data not available | -- |
-- |
-- |
-- |
-- |
|
-- |
-- |
Neomycin + Bacitracin | P,S,T | Ointment | 0.85 | 17th | 2087 | 20.08.2014 | 53.75% | -- |
|
-- |
-- |
Povidone Iodine | P,S,T | Solution | 0.39 | 1st | 1651 | 14.06.2013 | 69.14% | -- |
|
-- |
-- |
Povidone Iodine | P,S,T | Ointment | 1.64 | 3rd | 1905 | 28.06.2013 | 57.89% | -- |
|
-- |
-- |
Silver Sulphadiazine | P,S,T | Cream | 0.21 | Proposed for 18th Authority meeting | 53.75% | -- |
|||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction | 53.75% | -- |
||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||
-- |
-- |
Therefore, PTR per unit | 0.64 X (1-53.75%) | 0.30 | -- |
-- |
-- |
-- |
-- |
||
-- |
-- |
Add: 16% Retailer Margin | -- |
0.05 | -- |
-- |
-- |
-- |
-- |
||
-- |
-- |
Ceiling Price per unit | -- |
0.35 | -- |
-- |
-- |
-- |
-- |
||
-- |
-- |
WPI factor @ 6.32% | -- |
0.02 | -- |
-- |
-- |
-- |
-- |
||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
0.37 | S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
|||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
6.2.1.8.2.1 | Cloxacillin 250 mg Injection | BIOCLOX 250 MG INJECTION 1 | -- |
-- |
1 | Each pack | 837731 | 100% | 5.65999973 | 5.66 |
-- |
Monopoly situation as M/s Biochem is the company manufacturing the formulation and has market share of 100% | -- |
-- |
-- |
-- |
||||||
-- |
PTR per unit | -- |
5.66 | -- |
-- |
-- |
-- |
-- |
|||
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
|||||
-- |
6.2 Antibacterials | -- |
-- |
-- |
|||||||
-- |
6.2.1 Beta lactam medicines | -- |
-- |
-- |
|||||||
-- |
Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | -- |
||
-- |
Cloxacillin | P,S,T | Capsules | Data Not available | -- |
-- |
-- |
||||
-- |
Cloxacillin | Capsules | 1.09 | Proposed for 18th Meeting | 46.59% | -- |
|||||
-- |
Cloxacillin | Injection | Under consideration | -- |
-- |
-- |
-- |
-- |
|||
-- |
Cloxacillin | Liquid | Data Not available | -- |
-- |
-- |
-- |
-- |
|||
-- |
-- |
-- |
-- |
Average Reduction | 46.59% | -- |
|||||
-- |
Therefore, PTR per unit | 5.66 X (1-46.59%) | 3.02 | -- |
-- |
-- |
-- |
||||
-- |
Add: 16% Retailer Margin | -- |
0.48 | -- |
-- |
-- |
-- |
||||
-- |
Ceiling Price per unit | -- |
3.50 | -- |
-- |
-- |
-- |
||||
-- |
WPI factor @ 6.32% | -- |
0.22 | -- |
-- |
-- |
-- |
||||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
3.72 | S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
|||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit | Ceiling price with 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
6.2.1.8.1.2 | Cloxacillin Capsule 500 mg | BIOCLOX 500 MG CAPSULE 10 | -- |
-- |
10 | Capsule | 14387646 | 92.91% | 17.56 | 1.76 | -- |
-- |
-- |
-- |
CLX 500 MG CAPSULE 10 | -- |
-- |
10 | Capsule | 128840 | 0.83% | 18.20 | 1.82 | -- |
-- |
-- |
-- |
KLOX 500 MG CAPSULE 15 | -- |
-- |
15 | Capsule | 969813 | 6.26% | 27.30 | 1.82 | -- |
-- |
-- |
-- |
15486298 | 100.00% | -- |
1.79 | 2.08 | |||||
-- |
-- |
-- |
-- |
Maximum | 1.82 | Minimum | 1.76 | |||||
-- |
-- |
As per the above there are 2 companies consisting of Market Share of 1% & Above | -- |
-- |
-- |
-- |
||||||
-- |
-- |
Sum of MAT value considered for price calculation | -- |
154.00 | (Rs. in Lakhs) | -- |
-- |
|||||
-- |
-- |
Sum of PTR per unit considered for price calculation | -- |
3.58 | -- |
-- |
-- |
|||||
-- |
-- |
Number of Packs considered | -- |
-- |
2 | -- |
-- |
-- |
||||
-- |
-- |
Ceiling Price | -- |
-- |
1.79 | -- |
-- |
-- |
||||
-- |
-- |
Add : 16% Retailer Margin | -- |
-- |
0.29 | -- |
-- |
-- |
||||
-- |
-- |
MRP (without local taxes) | -- |
-- |
2.08 | -- |
-- |
-- |
||||
-- |
-- |
% Reduction with compared to Highest Price | -- |
-- |
1.65% | -- |
-- |
-- |
||||
-- |
-- |
WPI factor @ 6.32% | -- |
-- |
0.13 | -- |
||||||
-- |
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
-- |
2.21 | S.O. 2353(E) dt. 15.9.2014 | -- |
|||||
| S.No | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 30th Sept. 2013 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
5.1.2.3 | Carbamazepine Syrup 100mg /5ml | TEGRITAL SYRUP 100 MG 100 ML x 1 (/5ML) | TEGRITAL | 100 mg/5ml | 100 | ML | 19268931 | 100.0% | 15.40 | 0.15 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
19268931 | -- |
-- |
-- |
-- |
-- |
Monopoly situation as M/s Novartis Intl is the only company manufacturing the formulation and has market share of 100% | -- |
||||||||
-- |
-- |
PTR per unit | -- |
0.15 | -- |
||||||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
||||||||
-- |
-- |
-- |
-- |
||||||||
-- |
Section: 5 – Anticonvulsants/ Antiepileptics | -- |
|||||||||
-- |
-- |
Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | -- |
-- |
-- |
Carbamazepine | P, S, T | Tablets | 0.70 | 13th | 1010 | 02.04.2014 | 29.41% | -- |
||
-- |
Carbamazepine | Tablets | 1.37 | 14th | 1157 | 28.04.2014 | 21.85% | -- |
|||
-- |
Carbamazepine | Syrup | Under Consideration | -- |
-- |
-- |
-- |
-- |
|||
-- |
-- |
-- |
-- |
-- |
-- |
Average Reduction% | 25.63% | -- |
|||
-- |
-- |
Therefore, PTR per unit | 0.15 X (1-25.63%) | 0.11 | -- |
||||||
-- |
-- |
Add: 16% Retailer Margin | -- |
0.02 | -- |
||||||
-- |
-- |
Ceiling Price per unit | -- |
0.13 | -- |
||||||
-- |
-- |
WPI factor @ 6.32% | -- |
0.01 | -- |
||||||
-- |
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
0.14 | S.O. 2360(E) dt. 15.9.2014 | -- |
|||||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 31.05.2012 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
25.2.2.1 | Dextromethorphan | DMR 30 MG Tablet 10 | -- |
30 mg | 10 | Tablet | 235303.4 | 100.00% | 54.22 | 5.42 |
-- |
-- |
-- |
-- |
-- |
-- |
235303 | 22.56% | Average | 5.42 | ||
-- |
-- |
Monopoly situation as M/s West Coast Pharma Works is the only company manufacturing the formulation | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
PTR per unit | -- |
5.42 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
||||
-- |
25.2: Antitussives | -- |
-- |
||||||||
| – | Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | – | ||
-- |
Codeine phosphate | S,T | Tablets | 0.92 | 16th | 1782 | 10.07.2014 | 13.71% | -- |
||
-- |
Codeine phosphate | Syrup | No Data | -- |
-- |
-- |
-- |
-- |
|||
-- |
Dextromethorphan | P,S,T | Tablets | Under Consideration | -- |
-- |
-- |
-- |
-- |
||
-- |
-- |
-- |
-- |
-- |
Average Reduction | 13.71% | -- |
||||
-- |
Therefore, PTR per unit | 5.42 X (1-13.71%) | 4.68 | -- |
-- |
-- |
-- |
||||
-- |
Add: 16% Retailer Margin | -- |
0.75 | -- |
-- |
-- |
-- |
||||
-- |
Ceiling Price per unit | -- |
5.43 | -- |
-- |
-- |
-- |
||||
-- |
WPI factor @ 6.32% | -- |
0.34 | -- |
-- |
-- |
-- |
||||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
5.77 | S.O. 2358(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
|||
| Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 31.05.2012 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|
| 27.7.0.1 | Thiamine | BENALGIS 100 MG TABLET 10 | -- |
100 mg | 10 | Tablet | 17056349 | 100.00% | 45.71999995 | 4.57 |
| 27.7.0.1 | Thiamine | THYMINE 100 MG TABLET 10 | -- |
100 MG | 10 | Tablet | 385 | 0.00% | 38.50 | 3.85 |
-- |
-- |
-- |
-- |
-- |
17056734 | 1635.57% | Average | 4.57 | ||
-- |
Monopoly situation as M/s Franco Indian Pharmaceuticals Ltd. is the only company manufacturing the formulation and has market share of 100% | -- |
-- |
-- |
-- |
|||||
-- |
PTR per unit | -- |
4.57 | -- |
-- |
-- |
-- |
|||
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
||||
-- |
Section: 27 – Vitamins and Minerals | -- |
-- |
-- |
||||||
| – | Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | – | – |
-- |
Ascorbic Acid | P,S,T | Tablets | No data | -- |
-- |
-- |
-- |
-- |
|
-- |
Ascorbic Acid | Tablets | No data | -- |
-- |
-- |
-- |
-- |
||
-- |
Calcium carbonate | P,S,T | Tablets | 1.68 | 7th | 2867 | 20.09.2013 | 18.45% | -- |
|
-- |
Calcium carbonate | Tablets | 1.67 | 5th | 2255 | 22.07.2013 | 24.33% | -- |
||
-- |
Multivitamins (As per Schedule V of Drugs and Cosmetics Rules) | P,S,T | Tablets | No data | -- |
-- |
-- |
-- |
-- |
|
-- |
Nicotinamide | P,S,T | Tablets | No data | -- |
-- |
-- |
-- |
-- |
|
-- |
Pyridoxine | P,S,T | Tablets | No data | -- |
-- |
-- |
-- |
-- |
|
-- |
Riboflavin | P,S,T | Tablets | No data | -- |
-- |
-- |
-- |
-- |
|
-- |
Thiamine | P,S,T | Tablets | Under Consideration | -- |
-- |
-- |
-- |
-- |
|
-- |
Vitamin A | P,S,T | Tablets Capsules | No data | -- |
-- |
-- |
-- |
-- |
|
-- |
No data | -- |
-- |
-- |
-- |
-- |
||||
-- |
No data | -- |
-- |
-- |
-- |
-- |
||||
-- |
Injection | 1.3 | Proposed for 18th AM | 26.15% | -- |
|||||
-- |
Vitamin D (Ergocalciferol) | P,S,T | Capsules | No data | -- |
-- |
-- |
-- |
-- |
|
-- |
Vitamin D (Ergocalciferol) | Capsules | No data | -- |
-- |
-- |
-- |
-- |
||
-- |
Added Medicines | -- |
-- |
-- |
-- |
-- |
||||
-- |
Calcium Gluconate | P,S,T | Injection | 9.95 | 7th | 2868 | 20.09.2013 | 35.67% | -- |
|
-- |
-- |
-- |
-- |
-- |
Average Reduction | 26.15% | -- |
|||
-- |
Therefore, PTR per unit | 4.57 X (1-26.15%) | 3.37 | -- |
-- |
-- |
-- |
|||
-- |
Add: 16% Retailer Margin | -- |
0.54 | -- |
-- |
-- |
-- |
|||
-- |
Ceiling Price per unit | -- |
3.91 | -- |
-- |
-- |
-- |
|||
-- |
WPI factor @ 6.32% | -- |
0.25 | -- |
-- |
-- |
-- |
|||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
4.16 | S.O. 2360(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 31.05.2012 | MAT % | PTR | Price per Unit |
|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
6.4.2.1.2.2 | Didanosine | DINEX EC 400 MG TABLET 30 | -- |
400 mg | 30 | Tablet | 4079334 | 100.00% | 904.9100044 | 30.16 |
-- |
-- |
-- |
-- |
-- |
-- |
4079334 | -- |
Average | 30.16 | ||
-- |
-- |
Monopoly situation as M/s Cipla Ltd. is the only company manufacturing the formulation and has market share of 100% | -- |
-- |
-- |
-- |
|||||
-- |
-- |
PTR per unit | -- |
30.16 | -- |
-- |
-- |
-- |
|||
-- |
-- |
Price fixed in the relevant sub-section for other drugs is as follows: | -- |
-- |
-- |
-- |
-- |
||||
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||||
-- |
Section: 27 – Vitamins and Minerals | -- |
-- |
-- |
|||||||
-- |
-- |
Medicines | Category | Route of Admn | MRP excl. local taxes (Rs./unit) | Meeting No. | S.O No | Date | % Reduction w.r.t. Highest Price | -- |
-- |
-- |
Didanosine | S,T | Tablet | 23.93 | 7th | 2840(E) | 20.09.2013 | 11.73% | -- |
||
-- |
-- |
-- |
-- |
-- |
Average Reduction | 11.73% | -- |
||||
-- |
Therefore, PTR per unit | 30.16 X (1-11.73%) | 26.62 | -- |
-- |
-- |
-- |
||||
-- |
Add: 16% Retailer Margin | -- |
4.26 | -- |
-- |
-- |
-- |
||||
-- |
Ceiling Price per unit | -- |
30.88 | -- |
-- |
-- |
-- |
||||
-- |
WPI factor @ 6.32% | -- |
1.95 | -- |
-- |
-- |
-- |
||||
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
32.83 | S.O. 2359(E) dt. 15.9.2014 | -- |
-- |
-- |
-- |
|||
| S.No. | Unique No. as per NLEM | Composition as per NLEM | Pack Description | BRANDS | Strength | Pack Size | Unit | MAT Value as on 31.05.2012 | MAT % | PTR | Price per Unit | – |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
-- |
6.2.1.4 | Cefotaxime Injection 500 mg | OMNATAX 500 MG INJECTION 2 ML | -- |
ABBOTT HEALTHCARE PVT. LTD | 500 mg | 1 | Each Pack | 4043635 | 0.76% | 14.68 | 14.68 |
-- |
-- |
-- |
CEFOTAX 500 MG INJECTION 1 | -- |
ABBOTT HEALTHCARE PVT. LTD | 500 mg | 1 | Each Pack | 256405 | 0.05% | 13.57 | 13.57 |
-- |
-- |
-- |
TAXIM 500 MG INJECTION 2 ML | -- |
ALKEM LABORATORIES LTD. | 500 mg | 1 | Each Pack | 423804094 | 79.75% | 16.29 | 16.29 |
-- |
-- |
-- |
OMNICEF 500 MG INJECTION 2 ML | -- |
ARISTO PHARMACEUTICALS PVT.LTD | 500 mg | 1 | Each Pack | 7373658 | 1.39% | 16.29 | 16.29 |
-- |
-- |
-- |
BIOTAX 500 MG INJECTION 2 ML | -- |
BIOCHEM PHARMACEUTICAL INDS | 500 mg | 1 | Each Pack | 75032452 | 14.12% | 16.29 | 16.29 |
-- |
-- |
-- |
Q TAX 500 MG INJECTION 1 | -- |
EMCURE PHARMACEUTICALS LTD | 500 mg | 1 | Each Pack | 502414 | 0.09% | 16.15 | 16.15 |
-- |
-- |
-- |
CEFAXIL (LEBEN) 500 MG INJECTION 1 | -- |
LEBEN LABORATORIES PVT.LTD | 500 mg | 1 | Each Pack | 609642 | 0.11% | 15.86 | 15.86 |
-- |
-- |
-- |
CEFLIN (LINCOLN) 500 MG INJECTION 2 ML | -- |
LINCOLN PHARMACEUTICALS LTD | 500 mg | 1 | Each Pack | 737278 | 0.14% | 14.84 | 14.84 |
-- |
-- |
-- |
CEFANTRAL 500 MG INJECTION 10 ML | -- |
LUPIN LTD | 500 mg | 1 | Each Pack | 10064799 | 1.89% | 16.25 | 16.25 |
-- |
-- |
-- |
CEFENTRAL 500 MG INJECTION 5 ML | -- |
LUPIN LTD | 500 mg | 1 | Each Pack | 276484 | 0.05% | 16.13 | 16.13 |
-- |
-- |
-- |
SIFOTAXIM 500 MG INJECTION 10 ML | -- |
MANEESH PHARMACEUTICALS LTD | 500 mg | 1 | Each Pack | 76431 | 0.01% | 16.29 | 16.29 |
-- |
-- |
-- |
OMINAX 500 MG INJECTION 2 ML | -- |
MAPRA LABORATORIES PVT. LTD | 500 mg | 1 | Each Pack | 1580520 | 0.30% | 15.44 | 15.44 |
-- |
-- |
-- |
DESATAX 500 MG INJECTION 5 ML | -- |
SHREYA LIFE SCIENCES PVT. LTD | 500 mg | 1 | Each Pack | 151032 | 0.03% | 15.70 | 15.7 |
-- |
-- |
-- |
ANTAX(SHRINIVAS) 500 MG INJECTION 1 | -- |
SHRINIVAS GUJARAT LABORATORIES PVT LTD | 500 mg | 1 | Each Pack | 28676 | 0.01% | 15.27 | 15.27 |
-- |
-- |
-- |
TROYCEF 500 MG INJECTION 2 ML | -- |
TROIKAA PHARMACEUTICALS LTD | 500 mg | 1 | Each Pack | 74539 | 0.01% | 16.29 | 16.29 |
-- |
-- |
-- |
C TAX 500 MG INJECTION 1 | -- |
ZUVENTUS HEALTHCARE LTD | 500 mg | 1 | Each Pack | 6602051 | 1.24% | 16.29 | 16.29 |
-- |
-- |
-- |
GENCEF 500 MG INJECTION 1 | -- |
ZYDUS CADILA | 500 mg | 1 | Each Pack | 205134 | 0.04% | 16.29 | 16.29 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
531419245 | 100.00% | -- |
16.26 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
Maximum | 16.29 | Minimum |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
||||||
-- |
-- |
As per the above there are 5 companies consisting of Market Share of 1% & Above | -- |
-- |
-- |
-- |
||||||
-- |
-- |
Sum of MAT value considered for price calculation | -- |
-- |
5232 | (Rs. in Lakhs) | -- |
|||||
-- |
-- |
Sum of PTR per unit considered for price calculation | -- |
-- |
97.54 | -- |
-- |
|||||
-- |
-- |
Number of Packs considered | -- |
-- |
-- |
6 | -- |
-- |
||||
-- |
-- |
Ceiling Price | -- |
-- |
-- |
16.26 | -- |
-- |
||||
-- |
-- |
Add : 16% Retailer Margin | -- |
-- |
2.6 | -- |
-- |
|||||
-- |
-- |
MRP (without local taxes) | -- |
-- |
18.86 | -- |
-- |
|||||
-- |
-- |
% Reduction with compared to Highest Price | -- |
0.18% | -- |
-- |
-- |
|||||
-- |
-- |
WPI factor @ 6.32% | -- |
-- |
1.19 | -- |
-- |
|||||
-- |
-- |
Revised Ceiling Price (including WPI but without local taxes) |
-- |
20.05 | S.O. 2350(E) dt. 15.9.2014 | -- |
||||||
| NLEM Unique No. | Composition as per NLEM | PACK_DESC | BRANDS | Company | Strength | Unit | MAT Sep’13 Value | MAT% | PTR Sep’13 | Price per Unit | Ceiling Price with 16% Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.1.0.2 | Cefotaxime Injection 250 mg | CEFOTAX INJ DRY VIAL 250 MG x 1 | CEFOTAX | ABBOTT* | 250 | 1 | 113007 | 5060.77% | 9.00 | 9.00 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | OMNATAX VIAL DRY+SOL 250 MG 2 ML x 1 | OMNATAX | ABBOTT* | 250 | 1 | 3056523 | 136879.67% | 11.23 | 11.23 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | TAXIM VIAL DRY+SOL 250 MG x 1 | TAXIM | ALKEM* | 250 | 1 | 250495104 | 11217873.00% | 12.35 | 12.35 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | OMNICEF INJ DRY VIAL 250 MG x 1 | OMNICEF | ARISTO PH | 250 | 1 | 5916378 | 264951.99% | 12.35 | 12.35 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | ORITAXIM VIAL DRY+SOL 250 MG x 1 | ORITAXIM | CADILA PH | 250 | 1 | 524321 | 23480.56% | 9.00 | 9.00 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | C-TAX INJ DRY VIAL 250 MG x 1 | C-TAX | EMCURE* | 250 | 1 | 5688567 | 254749.98% | 12.35 | 12.35 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | Q-TAX INJ VIAL 250 MG 5 ML x 1 | Q-TAX | EMCURE* | 250 | 1 | 345804 | 15486.07% | 12.14 | 12.14 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | HALTAX INJ DRY VIAL 250 MG x 1 | HALTAX | HINDUSTAN | 250 | 1 | 2652803 | 118799.96% | 12.35 | 12.35 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | TOX INJ DRY VIAL 250 MG x 1 | TOX | LABORATE | 250 | 1 | 558882 | 25028.30% | 8.25 | 8.25 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | CEFAXIL INJ DRY VIAL 250 MG x 1 | CEFAXIL | LEBEN LAB | 250 | 1 | 325810 | 14590.69% | 11.57 | 11.57 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | CEFANTRAL VIAL DRY+SOL 250 MG 5 ML | CEFANTRAL | LUPIN LIMI | 250 | 1 | 6085640 | 272532.02% | 12.35 | 12.35 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | OMINAX INJ DRY VIAL 250 MG x 1 | OMINAX | MAPRA LAB | 250 | 1 | 3160403 | 141531.71% | 12.03 | 12.03 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | STANCEF INJ DRY VIAL 250 MG x 1 | STANCEF | RANBAXY* | 250 | 1 | 135943 | 6087.91% | 11.69 | 11.69 | -- |
| 24.1.0.2 | Cefotaxime Injection 250 mg | BIOTAX VIAL DRY+SOL 250 MG x 1 | BIOTAX | ZYDUS CA | 250 | 1 | 79593385 | 3564414.91% | 12.35 | 12.35 | -- |
-- |
358652570 | 16061467.53% | -- |
12.32 | 14.29 | ||||||
-- |
maximum | 12.35 | minimum | 12.14 | -- |
||||||
-- |
As per the above there are 5 companies consi | -- |
-- |
-- |
-- |
||||||
-- |
Sum of MAT value considered for price calculat | -- |
3,481.25 | (Rs. In Lakhs | -- |
||||||
-- |
Sum of PTR per unit considered for price calcul | -- |
73.89 | -- |
-- |
||||||
-- |
Number of Packs considered | -- |
6 | -- |
-- |
||||||
-- |
Average PTR | -- |
12.32 | -- |
-- |
||||||
-- |
Add : 16% Retailer Margin | -- |
1.97 | -- |
-- |
||||||
-- |
Ceiling Price (without local taxes) | -- |
14.29 | -- |
-- |
||||||
-- |
% Reduction with compared to Highest Price | -- |
0.24% | -- |
-- |
||||||
-- |
-- |
-- |
-- |
-- |
|||||||
-- |
WPI increase on 1 April, 2014 | -- |
6.32% | -- |
|||||||
-- |
Ceiling Price after WPI Adjustment | -- |
15.19 | S.O. 2350(E) dt. 15.9.2014 | -- |
||||||
Last Page Updated: 11-01-2019
Copyright © 2023 - All Rights Reserved- Official Website of National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Government of India
Note :Website Content Managed by National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Designed, Developed and Hosted by National Informatics Centre Services Inc.(NICSI)